
MFT TRUST FORMULARY



	BNF Chapter
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

Version 10.11 (November 2025)



Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

Formulary status definitions

Formulary (OK to be prescribed - but after any 1st or 2nd line options)

1st line formulary (when there are few formulary options, this is the 1st choice)

2nd line formulary (when there are few formulary options, this is the 2nd choice)

Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.

1st line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



GMMMG Red/Amber/Green classifications



RED

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

AMBER

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP).

See here for a list of GMMMG approved SCPs.

GREEN

Drugs that are suitable for initiation and ongoing prescribing within primary care.

SA

Green following specialist advice. Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

SI

Green following specialist initiation. Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

(DNP)

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns.

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

GREY

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

отс

In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care.



Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be annotated as follows: drug name

Formulary symbols

MMC	Medicines Management Committee decisions
emc⊛	Electronic medicines compendium (SmPC & PIL)
BNF	British National Formulary (BNF)
BNF for children	British National Formulary for Children (BNFC)
NICE	NICE guidance
PbR X	NHS Payment Scheme (NHSPS) excluded medicine (previously known as PbR excluded)
<u>ca</u>	Controlled Drug
0	Unlicensed medicine
33	High cost medicine
blueteq	Blueteq enabled forms
MedTeq	MedTeq Enabled Forms
NOT STOCKED	Not routinely stocked, can be ordered if existing patient supply is exhausted

PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY

GMMMG

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (No password required)

British National Formulary for Children (No password required)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

Section 1: Gastro-Intestinal system

Supported by the formulary (click here)



1.1 Dyspepsia & gastro-oesophageal reflux disease

- 1.1.1 Antacids & Simeticone
- 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

1.2 Anti-spasmodics & other drugs altering gut motility

Antimuscarinics Other Antispasmodics Motility Stimulants

1.3 Antisecretory drugs & mucosal protectants

- 1.3.1 H₂-Receptor Antagonists
- 1.3.3 Chelates & Complexes
- 1.3.5 Proton Pump Inhibitors

1.4 Acute diarrhoea

1.4.2 Antimotility Drugs

1.5 Chronic bowel disorders

- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids & Enemas
- 1.5.3 Drugs Affecting the Immune Response

Advanced therapies (biologic and targeted synthetic treatments)

1.6 Laxatives

- 1.6.1 Bulk-forming Laxatives
- 1.6.2 Stimulant Laxatives
- 1.6.3 Faecal Softeners
- 1.6.4 Osmotic Laxatives
- 1.6.5 Bowel Cleansing Preparation
- 1.6.6 Peripheral opioid-receptor antagonists
- 1.6.7 Other drugs used in constipation

1.7 Local preparations for anal & rectal disorders

- 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids
- 1.7.4 Management of anal fissures

1.9 Drugs affecting intestinal secretions

- 1.9.1 Drugs affecting biliary composition & flow
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin

1.10 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

GASTRO / ENDOSCOPY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Faecal Incontinence (CG49)

Irritable Bowel Syndrome (CG61)

Diarrhoea and vomiting in children under 5 (CG84)

Constipation in children and young people (CG99)

Acute upper GI bleeding (CG141)

Dyspepsia and gastro-oesophageal reflux disease (CG184)

Coeliac disease: recognition, assessment and management (NG20)

Crohn's disease: management (NG129)
Ulcerative colitis: management (NG130)

Ulcerative colitis (acute exacerbations) - infliximab (TA163)

Crohn's disease - infliximab & adalimumab (TA187)

Constipation (women) - prucalopride (TA211)

Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)

Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

Naloxegol for treating opioid induced constipation (TA345)

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

Obeticholic acid for treating primary biliary cholangitis (TA443)

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

Naldemedine for treating opioid-induced constipation (TA651)

Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)

Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

Teduglutide for treating short bowel syndrome (TA804)

Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

Elafibranor for previously treated primary biliary cholangitis (TA1016)

Mirikizumab for treating moderately to severely active Crohn's disease (TA1080)

Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)


GMMMG Formulary


Formulary Homepage

Chapter 1: Gastro-Intestinal system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List








Gastro-Intestinal System




Other PPIs are not available at this Trust










1.6.6 Peripheral opioid-receptor antagonists		
Methylnaltrexone bromide		RESTRICTED Adults, Palliative Care only
injection	BNF emco	
Naldemedine SI		RESTRICTED Adults only in line with TA651
200 microgram tablets	NICE MMC BNF EMC®	
Naloxegol SA		RESTRICTED Adults only in line with TA345
12.5mg; 25mg tablets	NICE MMC BNF EMC®	
1.6.7 Other drugs used in constipation		
Prucalopride SI		RESTRICTED - Adult women, Gastro. Consultants only
1mg; 2mg tablets	NICE MMC BNF emc	
Linaclotide SI		RESTRICTED - 3 rd line use Adults Gastro. Consultants only
290 micrograms capsules	MMC BNF emc	

1.7 Local preparations for anal & rectal disorde	rs	Gw <mark>M</mark> MG
1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids		
Anusol®		
GREEN OTC	BSINIF for children	
ointment	BNF emc	
Proctosedyl®		
GREEN	SINIE for children	
ointment	BNF emc	
Scheriproct®		
GREEN	ISINIP for children	
ointment; suppositories	BNF emc	
1.7.4 Management of anal fissures		
Glyceryl trinitrate GREEN		1 st line for anal fissure
Rectogesic® 0.4% ointment	IMC BNF emco	
Diltiazem hydrochloride SI		
2% cream: ointment	RNE emco	





WIFT FORMULALLY VIO. 11 (NOVEMBER 2025)	Section 1		Gasti o-intestinai System
Non-Formulary Items			G <mark>м</mark> МG
Darvadstrocel (DNP)			REJECTED in line with NICE TA556
Alofisel® 5 million cells/mL injection	NICE MMC	emc⊛	Criterion 1
Diarrhoea (adults) (DNP)			in line with GMMMG / NHSE
Dicycloverine hydrochloride (DNP)	RN		in line with GMMMG
	BNI	emc	Criterion 2
Haemorrhoids (DNP)			in line with GMMMG / NHSE
Indigestion and heartburn (DNP)			in line with GMMMG / NHSE
Infant colic (DNP)			in line with GMMMG / NHSE
Infrequent constipation (duration less than 2 weeks) (DNP)			in line with GMMMG / NHSE
IQoro (DNP)			in line with GMMMG
Neuromuscular training device			Criterion 1
Lactase drops (ONP)			in line with GMMMG
e.g Colief®			Criterion 1
Lubiprostone			Discontinued Jan-19
capsules	NICE MMC	emc⊚	
Macrogols	BN	5	Discontinued Apr-24
Klean-Prep® oral powder OTC haemorrhoid preparations	MMC BNI	emc⊚	
(DNP)	NICE BN	emco	in line with GMMMG
Racecadotril (DNP)			in line with GMMMG
capsules; granules for oral suspension; tablets		emc⊚	Criterion 1
Ranitidine			Discontinued Nov-19 EUROPEAN MEDICINES AGENCY SCHINGS MEDICINES HEATH
150mg; 300mg tablets Rifaximin (DNP)		emc _®	in line with GMMMG for Traveller's diarrhoea
200mg tablets (see also section 5.1.7) Stoma deodorant sprays (DNP)	NICE MMC BNI	emco)	in line with GMMMG
			Criterion 3
VSL#3® / Vivomixx® food supplement (DNP)			in line with GMMMG
			Criterion 1

Section 2: Cardiovascular system

Supported by the formulary (click here)



2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

2.3 Anti-arrhythmic drugs

2.3.2 Drugs for Arrhythmias

2.4 Beta-adrenoceptor blocking drugs

2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
 - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
 - 2.5.5.2 Angiotensin-II Receptor Antagonists
 - 2.5.5.3 Renin Inhibitors
 - 2.5.5.4 Heart Failure

2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

2.9 Antiplatelet drugs

2.10 Stable angina, acute coronary syndromes & fibrinolysis

2.10.2 Fibrinolytic Drugs

- 2.11 Antifibrinolytic drugs & haemostatics
- 2.12 Lipid-regulating drugs
- 2.13 Local sclerosants
- 2.14 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)

CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Familial hypercholesterolaemia (CG71)

Chest pain of recent onset (CG95)

Stable angina (CG126)

Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

Chronic heart failure in adults: diagnosis and management (NG106)

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

Hypertension in pregnancy: diagnosis and management (NG133)

Hypertension in adults: diagnosis and management (NG136)

Acute coronary syndromes (NG185)

Atrial fibrillation: diagnosis and management (NG196)

Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

Acute coronary syndromes - glycoprotein Ilb/Illa inhibitors (review) (TA47)

Myocardial infarction - thrombolysis (TA52)

Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)

Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated bt TA95 & TA126)

Hypercholesterolaemia - Ezetimibe (TA132)

Coronary artery disease - drug eleuting stents (TA152)

Venous thromboembolism - dabigatran (TA157)

Rivaroxaban for the prevention of VTE (TA170)

Atrial Fibrillation - dronedarone (TA197)

Vascular disease - clopidogrel and dipyridamole (TA210)

Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)

Acute coronary syndromes - ticagrelor (TA236)

Venous thromboembolism - apixaban (hip and knee surgery) (TA245)

Atrial fibrillation - dabigatran etexilate (TA249)

Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)

Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)

Stroke (acute, ischaemic) - alteplase (TA264)

Chronic heart failure - ivabradine (TA267)

Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)

Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)

Prasugrel with PCI for treating ACS (review of TA182) (TA317)

Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

lcosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

Tenecteplase for treating acute ischaemic stroke (TA990)

Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)


GMMMG Formulary


Formulary Homepage


Chapter 2: Cardiovascular system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List








		•
2.4 Beta-adrenoceptor blocking drugs		Gм <mark>₩</mark> мG
		NICE NG106
		NICE NG136
2.4 Beta-Adrenoceptor Blocking Drugs		NICE NG196
Atenolol		
GREEN	-1K(G)	
ablets; liquid; injection	BNF emc	
Bisoprolol fumarate		RESTRICTED adults.
GREEN		Cardiology Consultant only
ablets	MMC BNF emc	
Carvedilol	<u>C</u>	RESTRICTED adults.
GREEN		Cardiology Consultant only
tablets	MMC BNF emco	ALSO 2ND LINE FOR VARICEAL BLEED
Esmolol hydrochloride	ence	RESTRICTED
•		I.V. only
injection	BNF emco	
Etilefrine hydrochloride	BNP CITICS	RESTRICTED Haematology
		Consultants - SCD
tablets	MMC	Concaranto CCD
Labetalol hydrochloride		RESTRICTED
GREEN		oral preps in pregnancy
	BINT: No colonida no	or at preps in pregnancy
tablets; injection	BNF emc	
Metoprolol tartrate		
	BUN (F	
tablets; injection	BNF emc	
Nadolol		RESTRICTED paeds. ventricula
		arrhythmias in long QT syndrome
tablets	MMC BNF emc	
Nebivolol		
tablets	BNF emc	
Propranolol hydrochloride		RESTRICTED
GREEN	BRIE	not in Cardiology
tablets; capsules; oral solution; injection	MMC BNF emc	
Sotalol hydrochloride		
tablets	BNF emc	


Filspari® tablets




NICE MMC BNF CMC

IgA nephropathy


Jardiance ® tablets





NICE MMC BNF emc



2.7 Sympathomimetics		Gм <mark>₩</mark> мG
2.7.1 Inotropic Sympathomimetics		
Dobutamine		RESTRICTED /. V.
	ISSNIA	Specialist use only
nfusion (see also section 18.1.1)	BNF emco	
Dopamine hydrochloride		RESTRICTED I.V.
	ISWIE	Specialist use only
nfusion (see also section 18.1.1)	BNF emco	
Dopexamine		RESTRICTED 1. V.
		Specialist use only
nfusion	BNF emc	
soprenaline hydrochloride		RESTRICTED I.V.
		Specialist use only
njection (see also section 18.1.1)	BNF emc	•
2.7.2 Vasoconstrictor Sympathomimetics		
Adrenaline acid tartrate O		Specialist use endoscopic sinus
		surgery
in 1000 (0.1%w/v) cutaneous solution)	MMC BNF emc	
Ephedrine hydrochloride		RESTRICTED I.V.
	15/3/1/6	Specialist use only
njection	BNF emco	
Metaraminol [©]		
	FILKRAI	
njection	BNF emco	
Midodrine		Specialist use Cardiology /
SI		Healthcare of the elderly
ablets	MMC BNF emc	
Noradrenaline acid tartrate		RESTRICTED I.V.
		Specialist use only
nfusion	BNF emco	
Phenylephrine hydrochloride		RESTRICTED I.V.
		Specialist use only
njection	BNF emco	
2.7.3 Cardiopulmonary Resuscitation		
Adrenaline / Epinephrine		
GREEN		
njection	BNF emco	









2.10 Stable angina, ACS & fibrinolysis	GM <mark>M</mark> MG
Stable angina (BNF treatment summary)	
Acute coronary syndromes (BNF treatment summary)	
Fibrinolytic Drugs (BNF treatment summary)	NICE CG126
2.10.2 Fibrinolytic Drugs	NICE NG128
Tenecteplase	
RED	
injection	MMC BNF emc
Streptokinase	
RED	BNF
infusion	BNF emc
Urokinase	
RED	BNF
injection	MMC BNF emco
Alteplase	
RED	RESTRICTED
injection; infusion	NICE MMC BNF emc


2.11 Antifibrinolytic drugs & haemostatics			GM <mark>M</mark> MG
Antifibrinolytic Drugs & Haemostatics			
Etamsylate			
tablets	BNF	emc⊛	
Tranexamic acid GREEN			
injection; tablets	BNF	emc⊕	
Aprotinin RED			RESTRICTED
infusion		emc⊛	
Aminocaproic acid			RESTRICTED
sachets	MMC	emc _®	
Efanesoctocog alfa RED E	BING F	blueteq	RESTRICTED Haematology as per NICE TA1051
	MMC BNF	<u>emc</u> ⊕	
Emicizumab RED EP Hemlibra® injection	MMC BNF	blue teq	RESTRICTED Haematology as per NHSE NHS England RESTRICTED Haematology as per NHSE Figland
Marstacimab RED (1)	DINE TO COME OF THE COME OF TH	blueteq	RESTRICTED Haematology as per NICE TA1073
Altuvoct ® injection Vonicog alfa RED	MMC BNF	blueteg	RESTRICTED Haematology as per NHSE
Vevvondi® injection	MMC RNE		NHS England



Lipid-regulating drugs		
Alirocumab		RESTRICTED adults. Lipid Clinic
RED		Consultants in line with TA393
Praluent® injection	PDRX NICE MMC BNF CMC	(a)
Bempedoic acid (see also Nustendi®)		RESTRICTED adults. Consultants in
GREEN		line with TA694
Nilemdo ® tablets	PBRX NICE MMC BNF CMC	
Bempedoic acid with ezetimibe (see also Nilemdo®)	CITE WING BRIP CITE	
GREEN (See also Mile Mid @)		RESTRICTED adults. Consultants in
		line with TA694
Nustendi ® tablets	PBRX NICE MMC BNF EMC	_
Evinacumab		RESTRICTED a dults. Consultants in
RED	BINIE bluate	line with TA1002
Repatha® injection	PBRX NICE MMC BNF EMC	0
Evolocumab		RESTRICTED. Lipid Clinic
RED	SINI bluete	
Panatha @ injection	for obtide or	TA204
Repatha® injection	PBRX NICE MMC BNF EMC	
Icosapent ethyl		RESTRICTED adults in line with
		NICE TA805
Vazkepa ® capsules	PBRX NICE MMC BNF emc	0
Inclisiran		RESTRICTED adults. Consultants in
GREEN		line with TA733
Leqvio® injection	PBRX NICE MMC BNF CMC	for Primary Care Referral
Lomitapide		RESTRICTED adults. Lipid Clinic
RED EE	Direct	0
1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	bluete	NHS
Lojuxta® capsules	PBRX MMC BNF emc	
Volanesorsen RED (12)		RESTRICTED adults. Lipid Clinic
KLD III	bluete	Consultants in line with HST13
Waylivra® injection	PBRX NICE MMC BNF emc	•

2.13 Local sclerosants	Gм <mark>₩</mark> мG
Local Sclerosants	
Ethanolamine oleate	
RED	
injection	emc⊛
Sodium tetradecyl sulfate	
RED	
injection	emc





Section 3

Supported by the formulary (click here)



3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers Inhaler Devices

Nebuliser Diluent

3.2 Corticosteroids

Compound preparations

3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants
- 3.6 Oxygen (refer to oxygen guidelines)
- 3.7 Mucolytics
- 3.8 Aromatic inhalations
- 3.9 Cough preparations
 - 3.9.1 Cough Suppressants

Cough Suppressants (Palliative Care ONLY)

- 3.9.2 Demulcent & expectorant cough preparations
- 3.10 Systemic Nasal Decongestants
- 3.11 Antifibrotics

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Idiopathic pulmonary fibrosis (CG163)

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

Asthma pathway (BTS, NICE, SIGN) (NG244)

Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

Venom anaphylaxis - immunotherapy pharmalgen (TA246)

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)

Reslizumab for treating severe eosinophilic asthma (TA479)

Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)

Benralizumab for treating severe eosinophilic asthma (TA565)

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)

Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

Dupilumab for treating severe asthma with type 2 inflammation (TA751)

Palforzia for treating peanut allergy in children and young people (TA769)

Tezepelumab for treating severe asthma (TA880)

lvacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis (TA988)

Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis in people 6yr & over (TA1085)

Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)

Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)


GMMMG Formulary

Formulary Homepage

Chapter 3: Respiratory system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




3.1.4 Compound Bronchodilator Preparations			GM <mark>M</mark> MG
Aclidinium bromide with formoterol fumarate dihydrate			3 rd line use
GREEN			COPD maintenance
Duaklir Genuair®	MMC	BNF emc	
Glycopyrronium bromide with formoterol fumarate			3 rd line use
GREEN			COPD maintenance
Bevespi Aerosphere®	MMC	BNF emc	
Glycopyrronium bromide with indacaterol maleate			3 rd line use
			COPD maintenance
Ultibro®	MMC	BNF emc	
Ipratropium bromide with salbutamol			
Combivent®		BNF emc	
Tiotropium bromide monohydrate with olodaterol hydrochloride			3 rd line use
GREEN			COPD maintenance
Spiolto Respimat®	MMC	BNF emco	
Umeclidinium bromide with vilanterol trifenatate			3 rd line use
GREEN			COPD maintenance
Anoro Ellipta®	MMC	BNF emc	
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers			GMMMG GMMMG GMMMG
Inhaler Devices			
Volumatic® (spacer inhaler)			
GREEN		BINIF for children	
Large volume device with mouthpiece	NICE	BNF emc®	
Aerochamber® Plus (spacer device)			
GREEN		ENF for children	
Standard device with mouthpiece; Standard device with adult face mask	NICE	BNF	
Able Spacer® (spacer device)			
GREEN	_	EINIF for children	
N	NICE MMC	BNF	
Nebuliser Diluent			
Sodium chloride GREEN			
		(SIN)F for children	
0.9% nebuliser diluent		BNF emc	







300mg; 600mg tablets



MMC


3.5 Respiratory stimulants & pulmonary surfactants		GM <mark>M</mark> MG
3.5.1 Respiratory Stimulants		
Doxapram hydrochloride		
injection (see also section 15.1.7)	BNF emc	
Caffeine citrate	ESNIT	RESTRICTED apnoea in premature babies
injection	MMC BNF emco	
3.5.2 Pulmonary Surfactants		
Poractant alfa		
RED ÉÉ		
Curosurf® liquid	PbR X BNF emc	

3.6 Oxygen (refer to oxygen guidelines)










3.8 Aromatic inhalations		GM <mark>₩</mark> MG
Aromatic Inhalations		
Benzoin Tincture, Compound, BP		
Friars' Balsam liquid	emc⊚	
Menthol and Eucalyptus Inhalation, BP 1980		
	EST IT	
inhalation vapour	RNE emco	



3.10 Systemic nasal decongestants

Systemic Nasal Decongestants

NO DRUGS ARE RECOMMENDED FROM THIS GROUP




NHSE: OTC prescribing reduction

GMMMG

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)





Chapter 4: Central nervous system

Supported by the formulary (click here



- 4.1 Hypnotics & anxiolytics
 - 4.1.1 Hypnotics
 - 4.1.2 Anxiolytics
 - 4.1.3 Barbiturates
 - 4.1.4 Other hypnotics and anxiolytics
- 4.2 Drugs used in psychoses & related disorders
 - 4.2.1 Antipsychotic Drugs
 - 4.2.2 Antipsychotic Depot Injections
 - 4.2.3 Drugs used for mania and hypomania
- 4.3 Antidepressant drugs
 - 4.3.1 Tricyclic & Related Antidepressant Drugs
 - 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
 - 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
 - 4.3.4 Other Antidepressant Drugs
- 4.4 CNS stimulants & drugs used for ADHD
- 4.5 Drugs used in the treatment of obesity
- 4.6 Drugs used in nausea & vertigo
- 4.7 Analgesics
 - 4.7.1 Non-Opioid Analgesics
 - 4.7.2 Opioid Analgesics
 - 4.7.3 Neuropathic Pain
 - 4.7.4 Antimigraine Drugs
- 4.8 Antiepileptic drugs
 - 4.8.1 Control of the Epilepsies
 - 4.8.2 Drugs Used in Status Epilepticus
- 4.9 Drugs used in Parkinsonism & related disorders
 - 4.9.1 Dopaminergic Drugs Used in Parkinsonism
 - 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
 - 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders
- 4.10 Drugs used in substance dependence
- 4.11 Drugs for dementia
- Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Obsessive compulsive disorder (OCD) & body dismorphic disorder (BDD) (CG31)

Management of Obesity (CG43) (replaces TA22, TA31 & TA46)

Drug misuse: opioid detoxification (CG52)

Depression with a chronic physical health problem (CG91)

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

Anxiety (CG113) (replaces CG22)

Neuropathic pain - pharmacological management (CG173)

Psychosis and schizophrenia in adults (CG178)

Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Eating Disorders: recognition and treatment (NG69)

Parkinsons's disease in adults (NG71)

Attention deficit hyperactivity disorder: diagnosis and management (NG87)

Stop smoking interventions and services (NG92)

Dementia: supporting people with dementia and their carers in health and social care (NG97)

Post-traumatic stress disorder (NG116)

Depression in children and young people: identification and management (NG134)

Epilepsies in children, young people and adults (NG217)

Depression in adults: treatment and management (NG222)

Motor Neurone Disease: Riluzole (TA20)

Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)

Drug Misuse: Methadone & Buprenorphine (TA114)

Drug Misuse: Naltrexone (TA115) Smoking Cessation: Varenicline (TA123) Schizophrenia - aripiprazole (TA213)

Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Bipolar disorder (children) - aripiprazole (TA292)

Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

Vortioxetine for treating major depressive episodes (TA367)

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome (TA615)

Galcanezumab for preventing migraine (TA659)

Cenobamate for treating focal onset seizures in epilepsy (TA753)

Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

Fremanezumab for preventing migraine (replacing TA631) (TA764)

Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)

Eptinezumab for preventing migraine (TA871)

Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Rimegepant for preventing migraine (TA906)

Rimegepant for treating migraine (TA919)

Daridorexant for treating long-term insomnia (TA922)

Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

Atogepant for preventing migraine (TA973)

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)


Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

GMMMG Formulary


Formulary Homepage

Chapter 4: Central nervous system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




4.1.3 Barbiturates NO DRUGS ARE RECOMMENDED FROM THIS GROUP 4.1.4 Other hypnotics and anxiolytics Daridorexant hydrochloride GREEN Quiviviq ® tablets RESTRICTED in line with NICE TA922 NOT for initiation in 2^{ry} care




4.2.3 Drugs used for mania and hypomania	
Lithium carbonate	PRESCRIBE BY BRAND NAME
AMBER RED	TREATER FOR THE PROPERTY OF TH
tablets; M/R tablets	BNF emc
Lithium citrate	PRESCRIBE BY BRAND NAME
AMBER RED	BNE
oral solution	BNF emc®
Valproic acid	
SI	
Gastro-resistant tablets	BNF emc
MHRA Drug Safety Update (Apr-19): Valproate medicines and serious ha	rms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance
MHRA Drug Safety Undate (May-10): Carbanenems: concomitant use wit	th valproic acid not recommended





Venlafaxine	RE	STRICTED
GREEN SI	· · · · · · · · · · · · · · · · · · ·	n by Psychiatrist
		ii by i sycillati ist
M/R capsules; tablets; M/R tablets	MMC BNF emc	
Mirtazapine		
GREEN		
tablets; orodisperible tablets; oral solution	MMC BNF emc	
Duloxetine	RE	STRICTED
GREEN	initiatio	n by Psychiatrist
gastro-resistant tablets	BNF emco	
Flupentixol		STRICTED
		n by Psychiatrist
		ii by i byomati ist
tablets	BNF emc®	
Reboxetine	RE	STRICTED
	initiatio	n by Psychiatrist
tablets	MMC BNF emc	
Tryptophan	RE	STRICTED
	initiatio	n by Psychiatrist
capsules	BNF emco	
Vortioxetine		STRICTED
GREY SA		
	_	n by Psychiatrist
tablets	NICE MMC BNF emco	





4.5 Drugs used in the treatment of obesity 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract Orlistat GREEN Capsules MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines













4.9 Drugs used in Parkinsonism & re	iated disord	ers		GM <mark>M</mark> MG
1.9.1 Dopaminergic Drugs Used in Parkinsonism				NICE NG71
Amantadine hydrochloride				RESTRICTED
SA				Specialist use only
apsules; oral solution	NICE	BNF	mc®	•
Apomorphine hydrochloride		DIVI	21110	RESTRICTED
AMBER				Specialist use only
ejection; infusion	NICE MA	MC BNF	mo	
IHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising		WIC BRIF		
Cabergoline	Thore or our did one of colo			RESTRICTED
SA				Specialist use only
ablets	NICE MI	MC BNF	mc	
Co-beneldopa	1001			RESTRICTED
SA				Specialist use only
1 M/D				opeoiding doc only
apsules; M/R capsules; dispersible tablets	NICE	BNF	emc	DECTRICTED
Co-careldopa SA				RESTRICTED Specialist use only
		for children		Specialist use only
blets; M/R tablets (DNP) intestinal gel	PbR X NICE	BNF	emc⊛	
Entacapone SA				RESTRICTED
				Specialist use only
ablets	NICE M	MC BNF (emc⊚	
oslevodopa with foscarbidopa				RESTRICTED
RED				Specialist use only
Produodopa ® 240mg/mL / 12mg/mL infusion	NICE MI	MC (BNF) (emc⊕	
Opicapone				RESTRICTED 2 nd line
GREY SA				Specialist use only
apsules	MI	MC BNF 6	emc⊛	
Pramipexole				RESTRICTED 3 rd line add-on use
SA				Specialist use only
ablets; M/R tablets	Mi	MC BNF	emc 🖲	
Rasagiline				RESTRICTED patients with end of
SA				dose fluctuations
ablets	MI	MC BNF 6	emc®	
Ropinirole				RESTRICTED
SA				Specialist use only
ablets; M/R tablets		BNF	emce	•
Rotigotine		DIVI	,,,,,o	RESTRICTED
SA				Specialist use only. NBM patient
ansdermal patches	NICE AM	MC BNF 6	mc	- i - i - i - i - i - i - i - i - i - i
Safinamide	MI		-111C (1)	RESTRICTED
SA				Specialist use only
phloto		MO	ma	opolicinot ase only
ablets Selegiline	WI	MC BNF 6	711C(1)	DESTRICTED
SA				RESTRICTED Specialist use only
				opecialist use Offig
blets		BNF	emc	
1.9.2 Antimuscarinic Drugs Used in Parkinsonism				
Orphenadrine hydrochloride		_		
		(B) N(F)		
ral solution		BNF	emc⊛	
Procyclidine (oral & IM)				
GREEN		(B) NI(F)		
ablets; oral solution; injection (see also section 18.1.1)		BNF	emc⊚	
rihexyphenidyl hydrochloride				
		for chidran	1	





4.11 Drugs for dementia		G⋈ <mark>Ж</mark> мG
1.11 Drugs for Dementia		NICE NG97
Donepezil hydrochloride SA		RESTRICTED Specialist use only
ablets; orodispersible tablets	NICE MMC BNF EMC	
Galantamine SA		RESTRICTED Specialist use only
M/R capsules	NICE BNF EMC®	
MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals		
Memantine hydrochloride		RESTRICTED
SA		Specialist use only
tablets; oral solution	NICE MMC BNF EMCO	
Rivastigmine		RESTRICTED
GREEN		Specialist use only
capsules; oral solution; transdermal patches	NICE MMC BNF CMC	

Non-Formulary Items		GMMG
Aspirin and codeine		in line with GMMMG
o-codaprin® tablets; dispersible tablets	BNF emco	Criterion 2
cannabis-derived, cannabis-based and hemp products		in line with GMMMG
(DNP)		
ith the exception of nabilone and Epidyolex® Dextropropoxyphene with paracetamol		Criterion 1
(DNP)		in line with GMMMG
co-proxamol®	NICE BNF @MC®	
Oosulepin hydrochloride (DNP)		in line with GMMMG
ablets; capsules	BNF emco	Criterion 1
Electromagnetic pulse therapy		in line with GMMMG
(DNP)		
ctiPatch® plontersen sodium		Criterion 1 MFT not a commissioned centre
RED		patients referred to NAC - Royal Fre
Vainzua® 45mg/0.8mL injection	MMC (BNF) (emc)	
Eptinezumab RED (f2)		
jection	MMC BNF emco	NOT STOCKED
renumab	300000	
RED (E)		NOT OTO STORY
rigection rgotamine-containing products	NICE MMC BNF emc	NOT STOCKED
(DNP)		in line with GMMMG
g. Migril®		Criterion 1
Sketamine (DNP)		in line with GMMMG
pravato ® nasal spray	NICE MMC BNF emco	Criterion 1
remanezumab	ionio Billio	
RED EE	blueteq	
ojection Galantamine	NICE MMC BNF emc	NOT STOCKED RESTRICTED
yaramanini C		Specialist use only
mg; 8mg & 12mg tablets	NICE BNF (emco)	
Galcanezumab RED (ff)		
jection	MMC BNF emco	NOT STOCKED
Ganaxolone	WWW BNF CITICS	
		in line with NICE
talmy ® 50mg/mL oral suspension	NICE MMC emc	
(DNP)	BNIE	in line with GMMMG
00microgram tablets	NICE MMC BNF emc	Criterion 2
nfrequent migraine		in line with GMMMG / NHSE
(em)		
evomepromazine		in the could common
(DNP)	BNF	in line with GMMMG
mg tablets	BNF emc	
Oxapine (DNP)		in line with GMMMG
halation powder	BNF	Criterion 1
leprobamate (DNP)		in line with GMMMG
blets		Criterion 1
leprobamate		
(ONP)		in line with GMMMG
ablets		Criterion 1
/ild toothache / teething		in line with GMMMG / NHSE
g. paracetamol, ibuprofen, teething gels.		

Million and distance and the desirable and the second of t	
Minor conditions associated with pain, discomfort and/or fever (DNP)	in line with GMMMG / NHSE
e.g. aches and sprains, headache, period pain, back pain	
Nicotine	in time with Changes
(DNP)	in line with GMMMG
e-Voke®, Voke® (Nicotine inhaler)	Criterion 1
Omaveloxolone	Not recommended by NICE
Skyclarys® 50mg hard capsules	
Oxycodone with naloxone	
(DNP) 🚵	in line with GMMMG
Targinact® M/R tablets MMC BNF @mc®	Criterion 2
Paracetamol and tramadol	in line with GMMMG
(DNP)	
tablets; effervescent tablets BNF @mc	Criterion 2
Paracetamol mixture / mucilage (DNP)	in line with GMMMG
500mg / 5mL for topical use in patients with sore mouth or throat resulting from cancer treatment	Criterion 1
Paracetamol with buclizine and codeine	
(DNP)	in line with GMMMG
Migraleve ® (all presentations)	Criterion 1
Paracetamol with isometheptene (DNP)	in line with GMMMG
Midrid® 325mg / 65mg capsules	Criterion 1
Pregabalin (ONP)	in line with GMMMG
Misabri® 82.5mg; 165mg 330mg prolonged-release tablets ■ BNF © (EMC®)	
Sufentanil citrate	
(DNP)	in line with GMMMG
Zalviso® 30microgram sublingual tablets BNF emc®	Criterion 2
Tafamidis RED	MFT not a commissioned centre
	patients referred to NAC - Royal Free
Vyndagel ® capsules MMC BNF @MC®	
Travel sickness (DNP)	in line with GMMMG / NHSE
Trimipramine	in line with GMMMG
(DNP)	
tablets; capsules BNF emc	Criterion 2
Vutrisiran RED	MFT not a commissioned centre patients referred to NAC - Royal Free
Amvuttra ® injection NICE MMC BNF @mC®	

Section 5

Section 5: Infections

Supported by the formulary (click here)



5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulfonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antitleprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5.1 sistemanis sistem
- 5.4.5 Leishmaniacides 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, Enterobius vermicularis)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

5.6 Miscellaneous

Non-Formulary Items

Trust Guidelines

MFT Adult Antimicrobial guidelines

MFT Paediatric Antimicrobial guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Bacterial meningitis and meningococcal septicaemia (CG102)

Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)

Hepatitis B (Chronic) (CG165)

Tuberculosis (NG33)

Sinusitis (acute): antimicrobial prescribing (NG79) Sore throat (acute): antimicrobial prescribing (NG84) Otitis media (acute): antimicrobial prescribing (NG91)

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

Cough (acute): antimicrobial prescribing (NG120)

Surgical site infections: prevention and treatment (NG125)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Hepatitis B: Entecavir (TA153)

Hepatitis B: Telbivudine (TA154)

Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)

Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)

Hepatitis B: Tenofovir disoproxil (TA173)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Sofosbuvir for treating chronic hepatitis C (TA330)

Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

Ledipasvir-sofosbuvir for treating chronic hepatitis C (TA363)

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Elbasvir-grazoprevir for treating chronic hepatitis C (TA413)

Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

Glecaprevir-pibrentasvir for treating chronic hepatitis C (TA499)

Sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C (TA507)

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Cabotegravir with rilpivirine for treating HIV-1 (TA757)

Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

Bulevirtide for treating chronic hepatitis D (TA896)

Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

Molnupiravir for treating COVID-19 (TA1056)

Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

GMMMG Formulary

Formulary Homepage

Chapter 5: Infections

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

RESTRICTED USE ANTIBIOTICS

- 1. Must be recommended / approved for use by consultant medical microbiologist
- 2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
- 3. Only available from Pharmacy

RESERVED USE ANTIBIOTICS

- 1. Can be used only in accordance with the restrictions outlined below.
- 2. Indication must be clearly documented on the prescription chart.
- 3. If being used outside of guidelines Microbiology approval must be sought as above

UNRESTRICTED USE ANTIBIOTICS

1. Can be used according to MFT Trust guidelines, (those drugs not marked Restricted or Reserved)

5.1 Antibacterial drugs 5.1.1 Penicillins 5.1.1.1 Benzylpenicillin & Phenoxymethylpenicillin Benzylpenicillin sodium (Penicillin G) 600mg injection Phenoxymethylpenicillin (Penicillin V)

GMMMG

BNF emc

Benzathine benzylpenicillin U

BNF emc BNF emc

RESTRICTED unlicensed treatment for syphilis

GMMMG

5.1.1.2 Penicillinase-Resistant Penicillins Flucloxacillin

MMC BNF emc

MMC BNF emc®

RESTRICTED infection caused by multi-resistant coliforms. **Micro only**

5.1.1.3 Broad Spectrum Penicillins **Amoxicillin**

capsules; injection; oral solution

capsules; oral suspension; injection

Temocillin

Co-amoxiclay

Timentin® 3.2g injection

5.1.1.5 Mecillinams

BNF emc

BNF emc

tablets: oral suspension: injection 5.1.1.4 Antipseudomonal Penicillins

Piperacillin with tazobactam Ticarcillin with clavulanic acid

RESERVED serious / resistant infections MMC BNF emc

MMC BNF emc

RESERVED serious / resistant infections

Pivmecillinam hydrochloride 200mg tablets

MMC BNF emc

RESTRICTED UTIs caused by resistant coliforms

5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams

5.1.2.1 Cephalosporins

BNF emc



caspules; tablets; oral suspension Cefazolin

MMC BNF emc®

RESTRICTED on Micro. advice only **RESERVED**

as per guidelines for children

iniection Ceftriaxone

injection Cefotaxime

Cefalexin

BNF emc BNF emc


RESERVED as per guidelines for children


injection Cefuroxime injection


BNF emc


RESERVED as per guidelines for children Section 5


Cefixime		RESERVED
	SUNUE for children	GU infections only
tablets	MMC BNF emc	
Ceftazidime		RESERVED
	FINAL P	pseudomonas infection in CF
injection	MMC BNF emc	
Cetazidime with avibactam		RESERVED for
		gram negative organisms
7	24240	Micro. Consultant only
Zavicefta ® infusion Ceftolozane sulfate with tazobactam sodium	MMC BNF emc	
Centolozane sunate with tazobactam socium		RESERVED for
		gram negative organisms
Zerbaxa® infusion	MMC BNF emc	Micro. Consultant only
Ceftaroline fosamil		RESERVED
		CAP & cSSTI treatment.
Zinforo ® infusion	MMC BNF emco	Micro. Consultant only
Cefoxitin		RESERVED for treatment of
		mycobacterium abscessus in CF.
injection	MMC BNF emc®	Micro. Consultant only
Cefiderocol		RESERVED for
		gram negative organisms
Fetcroja® infusion		
•	MMC BNF emc	micro. Consultant Unity
5.1.2.2 Carbapenems		
Ertapenem		RESTRICTED
	SSINUE for shielders	Outpatient therapy only
infusion	MMC BNF emc	
Imipenem with cilastatin		RESTRICTED
	[8]N/[F	Non-Tuberculous Mycobacteria in CF
infusion	MMC BNF emco	_
Imipenem with cilastatin & relebactam	WIW BAP CITES	
EE		RESTRICTED
Recarbrio ® infusion	MMC BNF emc	Micro. Consultant only
Meropenem		RESERVED
	ESINE for children	as per guidelines
injection	MMC BNF emc	
Meropenem with vaboractam		0505010550
		RESTRICTED
Vaborem ® infusion	MMC BNF emc	Micro. Consultant only
5.1.2.3 Other Beta-Lactam antibiotics	WING CHICS	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Aztreonam		RESTRICTED
ALTOONGIN		gram negative organisms
	ESTRUCE (State of the Control of the	gram negative organisms
injection	BNF emc	
Aztreonam lysine		RESTRICTED 3 rd line CF patients with
RED EE	SINGS for children	chronic pulmonary infection
Cayston® nebuliser solution	MMC BNF emc	
Aztreonam with avibactam sodium		
Emblaveo® infusion	MMC BNF emc	
5.1.3 Tetracyclines	WING BILL	
Doxycycline		
	SS MAP for children	
capsules; tablets; dispersible tablets	MMC BNF emc	
Oxytetracycline		
	BINIE	
tablets	BNF emco	
Demeclocycline hydrochloride		RESTRICTED
		SIADH only
capsules (see also section 6.5.2)	MMC BNF emc	
Lymecycline	WIMIC BRF CITCO	RESTRICTED
	E) N TO	Non-Formulary
408mg capsules (see also section 13.6.2)	MMC BNF emc	MMC approved for GP referral
Minocycline		
	SIME	
capsules; tablets	MMC BNF emc	
Tigecycline		RESERVED
	ENNIE	as per guidelines
infusion	MMC BNF emco	



























5.4.5 Leishmaniacides	
Meglumine antimoniate 🏻 🛈	RESTRICTED
RED	treatment of Leishmaniacides
njection	MMC BNF emco
Paromomycin	RESTRICTED
RED	treatment of Crypotosporidiosis
ablets	MMC BNF emco
Sodium stibogluconate	RESTRICTED
RED	treatment of Leishmaniacides
njection	MMC BNF emco
5.4.7 Drugs for toxoplasmosis	
Sulfadiazine 🕛	RESTRICTED
RED	treatment of toxoplasmosis
ablets	BNF emc micro. recommendation only
5.4.8 Drugs for pneumocystis pneumonia	
Atovaquone U	RESTRICTED
RED	Specialist use only
oral suspension	BNF emc
Pentamidine isethionate	RESTRICTED
RED	Specialist use only
njection	BNF emc



5.6 Miscellaneous			GM <mark>₩</mark> MG
5.6 Miscellaneous antimicrobial treatments			
Calcium sulphate			RESTRICTED Specialist use Diabetic Foot Clinic
Stimulan® antibiotic carrier beads	MMC	emc⊚	only
Taurolidine			DECEDIATED.
RED			RESTRICTED Aspergilloma surgery only
TauroPace™ 2% solution	MMC	emc	risperginentia cargory crity



Section 6: Endocrine system



6.1 Drugs used in diabetes

6.1.1 Insulins

6.1.1.1 Short-acting insulins

6.1.1.2 Intermediate & long-acting insulins

Biphasic insulins

6.1.2 Antidiabetic drugs

6.1.2.1 Sulphonylureas

6.1.2.2 Biguanides

6.1.2.3 Other antidiabetic drugs

Alpha glucosidase inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Rapid acting insulin secretagogues (meglitinides)

Glucagon-like peptide-1 (GLP-1) receptor agonists

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Thiazolidinediones

6.1.4 Treatment of hypoglycaemia

6.1.5 Treatment of diabetic nephropathy and neuropathy

6.1.6 Diagnostic and monitoring agents for diabetes mellitus

6.2 Thyroid & antithyroid drugs

6.2.1 Thyroid hormones

6.2.2 Antithyroid drugs

6.3 Corticosteroids

6.3.1 Replacement therapy

6.3.2 Glucocorticoid therapy

6.4 Sex hormones

6.4.1 Female sex hormones and their modulators

6.4.1.1 Oestrogens & HRT

6.4.1.2 Progestogens and progesterone receptor modulators

6.4.2 Male sex hormones & antagonists

6.5 Hypothalamic and pituitary hormones & anti-oestrogens

6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

6.5.2 Posterior pituitary hormones & antagonists

6.6 Drugs affecting bone metabolism

6.6.1 Calcitonin & parathyroid hormone

6.6.2 Bisphosphonates & other drugs affecting bone metabolism

6.7 Other endocrine drugs

6.7.1 Bromocriptine & other dopaminergic drugs

6.7.2 Drugs affecting gonadotrophins

6.7.3 Metyrapone

6.7.4 Somatomedins

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Safer insulin prescribing (KTT20)

Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

Type 1 diabetes in adults: diagnosis and management (NG17)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

Diabetic foot problems: prevention and management (NG19)

Type 2 diabetes in adults: management (NG28)

Heavy menstrual bleeding: assessment and management (NG88)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Human growth hormone - adults (TA64)

Diabetes (type 1) - insulin pump therapy (TA151)

Osteoporosis - Primary Prevention (TA160)

Osteoporosis - Secondary Prevention (TA161)

Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)

Osteoporotic Fractures - denosumab (TA204)

Bone metastases from solid tumours - denosumab (TA265)

Type 2 diabetes - Dapagliflozin combination therapy (TA288)

Diabetes (type 2) - canagliflozin (TA315)

Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Bisphosphonates for treating osteoporosis (TA464)

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Sotagliflozin with insulin for treating type 1 diabetes (TA622)

Liraglutide for managing overweight and obesity (TA664)

Romosozumab for treating severe osteoporosis (TA791)

Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

Somatrogon for treating growth disturbance in people 3 years and over (TA863)

Tirzepatide for treating type 2 diabetes (TA924)

Empagliflozin for treating chronic kidney disease (TA942)

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

Abaloparatide for treating osteoporosis after menopause (TA991)

Burosumab for treating X-linked hypophosphataemia in adults (TA993)

Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

Tirzepatide for managing overweight and obesity (TA1026)

Relugolix-estradiol-norethisterone for treating symptoms of endometriosis (TA1057)

Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)

Linzagolix for treating symptoms of endometriosis (TA1067)

Dapagliflozin for treating chronic kidney disease (updates & replaces TA775) (TA1075)


GMMMG Formulary

Formulary Homepage


Chapter 6: Endocrine system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




Long-acting insulins		
Human		
Levemir®		
SI	[8][N]S	
Insulin detemir	MMC BNF emc	
Lantus®	MIMIO ENTE	2 nd line use
	(in patients where normal basal insulins
	[5]NIP for oblideer	
Insulin glargine	MMC BNF emc	cause nocturnal hypoglycaemia
Abasaglar®		
	(B)(N)(F) for children	
Insulin glargine (biosimilar)	MMC BNF emc	
Toujeo® GREY SA		
GREY SA	(SINIF	
Insulin glargine (HIGH STRENGTH)	MMC BNF emc	
Tresiba®		RESTRICTED
GREY SI		3 rd line after Levemir & Lantus
Insulin degludec	MMC BNF emc	Diabetes Consultant only
MHRA Drug Safety Update (Apr-13): Insulin degludec (Tresiba ▼): available in additional higher strength		
Biphasic insulins		
Human		
Humalog® Mix 25		
SI	,8JNJF	
Biphasic insulin lispro	BNF emc	
Humalog® Mix 50	(2	
SI		
Biphasic insulin lispro	BNF emc	0
Humulin M3®	BNP (CITIC	9
SI		
Disharia isashara isashira	(CXTVICT) for children	
Biphasic isophane insulin NovoMix® 30	BNF emc	<u></u>
SI SI		
	BIRUF for children	
Biphasic insulin aspart	MMC BNF emc	
Animal		
Some long-standing type 1 diabetic patients may be on animal insulin. These are made by	/ Wockhardt and come ir	10ml vials or 3ml Cartridges that fit into the
Autopen Classic® which is available on prescription. • Patients need not be transferred to human insulin unless clinical need dictates		
Human insulin and analogues should be used in preference to animal insulin		
Hypurin® Porcine 30/70 Mix Insulin		
Trypurm © Forcine 30/70 mix msum	E-1000-	
	ESURUL ** for shilldren	
Biphasic isophane insulin	BNF emc	
6.1.2 Antidiabetic drugs		
6.1.2.1 Sulfonylureas		
Gliclazide GREEN		
GREEN	EIRUF for children	
tablets	BNF emc	
Glipizide		RESTRICTED
		Not for initiation
tablets	BNF emc	0
6.1.2.2 Biguanides		
Metformin hydrochloride		
GREEN SI	[8]K0[F	
oral solution; tablets	MMC BNF emc	
MHRA Drug Safety Update (Jun-22): Metformin and reduced vitamin B12 levels: new advice for monitori		
MHRA Drug Safety Update (Mar-22): Metformin in pregnancy: study shows no safety concerns		
6.1.2.3 Other antidiabetic drugs		NICE NG28
Alpha glucosidase inhibitors		
Acarbose		
tablets	BNF emc	
Dipeptidyl peptidase 4 (DPP 4) inhibitors		
MHRA Drug Safety Update (Sep-12): Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis		
Alogliptin		
GREEN		
tablets	MMC BNF emc	
Linagliptin	(5	
GREEN		
tablets	MMC BNF emc	









6.4 Sex hormones		GMMG
6.4.1 Female sex hormones and their modulators		
6.4.1.1 Oestrogens & HRT		
Conjugated oestrogens with progestogen		
Premique® (Conjugated oestrogens with medroxyprogesterone)		2 nd line use oral
GREEN		(continuous combined HRT)
tablets	BNF emc	9
Estradiol with Progestogen		
Bijuve® (Estradiol with progesterone)		
GREEN		
1mg/100mg capsules	MMC BNF emc	
Elleste-Duet® (Estradiol with norethisterone)		1 st line use oral
		(sequential HRT)
tablets	BNF emc	9
Evorel Conti® (Estradiol with norethisterone)		
Evorel Sequi® (Estradiol with norethisterone)	MMC BNF emc	9
GREEN (EStraction with notethisterone)		
patch		
Femoston® (Estradiol with dydrogesterone)	MMC BNF emc	2 nd line use oral
GREEN (Estraction with dydrogesterone)		(sequential HRT)
tablets	BNF emc	
Kliovance® (Estradiol with norethisterone)	BNF	1 st line use oral
GREEN (L'Stradior With Horethisterone)		(continuous combined HRT)
tablets	MMC BNF emc	,
Estradiol only		9)
Elleste Solo®		1 st line use oral
GREEN		(oestrogen only HRT)
tablets	BNF emc	_
Estradot®	<u> </u>	RESTRICTED
GREEN		(Oestrogen only HRT)
		when oral contraindicated.
patch Francis	BNF emc	
Evorel® GREEN		RESTRICTED
		Paed. Endocrine Consultants
Lenzetto®	MMC BNF emc	
GREEN		
transdarmal apray	MANO COMP.	
transdermal spray Oestrogel®	MMC BNF emc	9
GREEN		
0.06% gel (pump-pack)	MMC BNF emc	
Progynova®	WIWIO BRIF CITIC	RESTRICTED 2 nd line
RED		Paed. Endocrine Consultants
1mg tablets	MMC BNF emc	
Sandrena®	-Allai Callic	
GREEN		
500microgram; 1mg gel sachets	MMC BNF emc	9
Ethinylestradiol, raloxifene & tibolone		
Ethinylestradiol		RESTRICTED
		adults: amenorrhoea
2 microgram tablets	MMC BNF emc	paeds: pubertal induction (3 rd line)
Raloxifene hydrochloride		RESTRICTED
SA		Specialist Med. Consultant only
tablets	NICE MMC BNF emc	NICE TA160 / TA161
Tibolone		3 rd line use oral
GREEN		(continuous combined HRT)
tablets	BNF emc	3
6.4.1.2 Progestogens and progesterone receptor modulators		
Dydrogesterone		
tablets	emc	
Medroxyprogesterone acetate GREEN		
SKEL	[8] N. [5] top_children	
Deno-Provera® 150mg/mL injection	DNE OMO	

Specialist use only tablets BNF emc MHRA Drug Safety Update (Apr-24): Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation..)

MHRA Drug Safety Update (May-17): Finasteride: rare reports of depression and suicidal thoughts

Anti-androgens Cyproterone acetate

Finasteride


GREEN


tablets (see also section 8.3.4.2)

RESTRICTED Specialist use only


RESTRICTED

BNF emce






Evenity ® injection



NICE MMC BNF emc



WF1 Formulary V10.11 (November 2025)	Section 6	Endocrine System
Non-Formulary Items		GM <mark>™</mark> MG
Buserelin acetate		Discontinued
		March 2025
uprecur® nasal spray	MMC BNF emc	
Carbimazole (DNP)		in line with GMMMG
	88880	
Omg; 15mg tablets Chlorpropamide	MMC BNF emc	
(DNP)		in line with GMMMG
ablets	BNF	Criterion 1
Fezolinetant	DNF	Official 1
leoza® 45mg tablets	BNF emc	
HRA Drug Safety Update (Apr-25): Fezolinetant ▼ (Veoza): risk of liver injury; ne Bliclazide	w recommendations to minimise risk	
(DNP)		in line with GMMMG
Indified release tablets (e.g. Diamicron® MP)	PNE OMC	Criterion 2
Modified-release tablets (e.g. Diamicron® MR) Hypurin® Bovine Isophane	BNF (emc)	Discontinued
.,		July 2017
sophane insulin	emco	
Hypurin ® Bovine Lente	<u> </u>	Discontinued
		July 2017
nsulin zinc suspension	emc⊚	
lypurin® Bovine Neutral		Discontinued
		July 2017
nsulin bovine	NICE (emco	
iraglutide		Weight loss - MFT is not a commissione
RED CONTROL OF THE CO		weight management service. Not for
	Greater Manchester Integrated Care Partners Transpared Care	initiation, only for patients initiated at NC
Saxenda® 6mg/mL pre-filled pen	NICE MMC BNF emco	
_ixisenatide		Discontinued
		June 2022 / December 2023
yxumia® 10 microgram; 20microgram injection	MMC BNF emc	
Metformin hydrochloride (DNP)		in line with GMMMG
g immediate-release tablets	BNF emc	Criterion 2
Nateglinide		Discontinued
		August 2020
Pen needles 8mm, 10mm, or 12mm in length	MMC BNF emc	
(DNP)		in line with GMMMG
		Criterion 1
Pen needles costing in excess of £5 per 100		
(DNP)		in line with GMMMG
		Criterion 3
Semaglutide		Weight loss - MFT is not a commissione
RED	Greater	weight management service. Not for
	Greater Manchester Integrated care Pertnership	initiation, only for patients initiated at NC
Vegovy® injection	NICE MMC BNF emc	
Sotagliflozin		Withdrawn
		August 2022
Zynquista ® 200mg tablets	NICE MMC emc®	
Firzepatide (DNP)		Weight loss - MFT is not a commissione
<u> </u>	Greater	weight management service. Not for
	Greater Manchester Integrated Care Partnership	initiation, only for patients initiated at NC
Mounjaro ® injection	NICE MMC BNF EMC®	

Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the formulary (click here)



7.1 Drugs used in Obstetrics

7.1.1 Prostaglandins & oxytocics

7.1.1.1 Drugs affecting the ductus arteriosus

7.1.2 Mifepristone

7.1.3 Myometrial relaxants

7.2 Treatment of vaginal & vulval conditions

7.2.1 Preparations for vaginal & vulval changes

7.2.2 Vaginal & vulval infections

7.3 Contraceptives

7.3.1 Combined hormonal contraceptives

Ethinylestradiol with Desogestrel

Ethinylestradiol with Gestodene

Ethinylestradiol with Levonorgestrel

Ethinylestradiol with Norelgestromin

Ethinylestradiol with Norethisterone

Ethinylestradiol with Norgestimate

Mestranol with Norethisterone

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

7.3.2.2 Parenteral progestogen-only contraceptives

7.3.2.3 Intra-uterine progestogen-only device

7.3.5 Emergency contraception

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

7.4.2 Drugs for urinary, enuresis & incontinence

7.4.3 Drugs used in urological pain

7.4.4 Bladder instillations & urological surgery

7.4.5 Drugs for erectile dysfunction

7.4.6 Drugs for premature ejaculation

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Long-acting reversible contraception (CG30)

Lower urinary tract symptoms (CG97)

Nocturnal enuresis - the management of bedwetting in children and young people (CG111)

Antenatal and postnatal mental health: clinical management and service guidance (CG192)

Heavy menstrual bleeding: assessment and management (NG88)

Urinary incontinence and pelvic organ prolapse in women: management (NG123)

Caesarean birth (NG192)

Antenatal care for uncomplicated pregnancies (NG201)

Inducing labour (NG207)

Intrapartum care for healthy women and babies (NG235)

Overactive bladder - mirabegron (TA290)

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Vibegron for treating symptoms of overactive bladder syndrome (TA999)


GMMMG Formulary

Formulary Homepage


Chapter 7: Obstetrics, gynaecology & urinary tract disorders


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List



7.2.1 Preparations for vaginal & vulval changes		
Destrogens, topical		
Estradiol		
GREEN		
/agifem® 10 microgram pessaries	BNF emco	
Estriol	Cinic S	
GREEN		
Ovestin ® 0.1% cream; Gynest® 0.01% cream	MMC BNF emc	
Estriol		
GREEN		
nvaggis® 0.03mg pessaries	MMC BNF emc	
Estriol		
GREEN		
/agirux® 10microgram vaginal tablet	MMC BNF emc	
stradiol (vaginal ring)		RESTRICTED
GREEN		Obs & Gynae Consultants only
string® 7.5 microgram / 24 hours ring	MMC BNF emc	
7.2.2 Vaginal & vulval infections		
Preparations for vaginal & vulval candidiasis		
Clotrimazole GREEN		
CREEN	ESTRUP for children	
ream; pessaries	BNF emco	
Miconazole		
	BINF for children	
aginal cream	BNF emco	
Preparations for other vaginal infections		
Clindamycin GREEN	F-100 F9-1	
	[S]N.F for children	
% vaginal cream Dequalinium chloride	BNF emco	RESTRICTED
RED		2 nd line - bacterial vaginosis (BV)
iluomizin® 10mg vaginal tablets	MMC CONC. OMCO	2 me - bacteriai vaginosis (bv)
Netronidazole	MMC BNF emc	RESTRICTED
GREEN	IEI WIEI	Obs & Gynae Consultants only
idoval® 0.75% vaginal gel	MMC BNF emc	
lystatin	MIMIO SINE CITICO	
•	lajnia L	
aginal cream; pessaries	BNF emco	
Boric acid 0	<u> </u>	RESTRICTED
RED		specialist use only for
	MMC emc	vulvovaginal candidiasis





	GM <mark>™</mark> MG
	NICE CG97
	NICE CG111
	NICE NG123
IF emc⊚	
	1 st line
QF	1 line
r emc⊚	
	NICE NG123
	1 st line in OAB
(IIF	i ilile ili OAB
r emc⊚	
	1 st line in OAB
	i illie ili OAD
i F emc⊕	
	1 st line in OAB
	i iiile iii OAD
r emc⊚	
	2 nd line in OAB
	2 IIIIe III OAD
emc®	
IF emc⊚	
	RESTRICTED
NE STATE OF THE ST	1 ^{RY} Care referral only
r emc⊚	
	RESTRICTED
	in line with TA290 / Paeds 3 rd line
emc®	
ular and cardiac	
	RESTRICTED
ama a	in line with TA999
F emc	
emco	RESTRICTED
	Haematology Consultants only
E Omco	
CITICO	
	RESTRICTED
	resistant calcium phosphate lithiasis
emca	European Association of Urology
CITIC	RESTRICTED
	Urology Cons. in line with NICE
Cmc	
CIIIC (1)	
E emc	
<u></u>	
emco	
CITIC®	
	if emco

7.4.4 Bladder instillations & urological surgery			
Chlorhexidine			
RED	ESTN for phate	(F	
0.02% irrigation solution	BN	F emc⊚	
Dimethyl sulfoxide U			
50% solution		emc⊚	
Glycine			
1.5% irrigation solution	BN	emc _®	
Sodium chloride RED	87	J.F	
0.9% irrigation solution	BN	emc _®	
Sodium citrate RED	ER		
3% irrigation solution Sodium hyaluronate	BN	emc®	RESTRICTED
RED			Urology Consultants only
Cystistat® 40mg/50mL bladder instillation	MMC	<u>emc</u> ⊚	
Sodium hyaluronate with sodium chondroitin sulfate			RESTRICTED Urology Consultants only
iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation	MMC	<u>emc</u>	
7.4.5 Drugs for erectile dysfunction			
Alprostadil GREEN	(B) N for child		RESTRICTED Urology Consultants only
cream; injection; urethral sticks Aviptadil with phentolamine mesilate	MMCEN	F emc⊚	DECTRICTED
SI			RESTRICTED Urology Consultants only
Invicorp® injection	MMC BN	emc _®	
Sildenafil GREEN or RED PAH	(S) M	I.E	RESTRICTED 1 ^{RY} Care referral only
injection; oral suspension; tablets (see also section 2.5.1)		emc _®	
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-uradalafil	ero exposure in a clir	nical trial on intraute	
GREEN OF RED PAH			RESTRICTED 1 ^{RY} Care referral only
tablets (see also section 2.5.1) Vardenafil	MMC BN	emc®	DESTRICTES
Varuellalli			RESTRICTED 1 ^{RY} Care referral only
tablets	MMC (BN	emc ₀	
7.4.6 Drugs for premature ejaculation (DNP)			
NOT STOCKED			

Non-Formulary Items	G™ <mark>™</mark> G	
Dapoxetine hydrochloride	in line with	
	GMMMG	
Priligy ® 30mg; 60mg tablets	BNF emc® Criterion	1
<u>Ooxaz</u> osin	in line with	h
(DNP)	GMMMG	
mg M/R tablets; 8mg tablets	BNF emc Criterion 2	2
icensed and off-label topical anaesthetics	in line witl	h
(DNP)	GMMMG	
	Criterion ²	1
// (DNP)	in line with GMMM	G / NHSE
.g. Potassium citrate mixture or sachets, cranberry products		
Fadalafil Fadalafil	in line witl	h
(DNP)	GMMMG	
.5mg tablets	BNF @mc Criterion 2	2
Tamsulosin with dutasteride	in line with	h
(DNP)	GMMMG	
100microgram / 500microgram hard capsules	BNF emc® Criterion	1

Section 8: Malignant disease & immunosuppression

Supported by the formulary (click here)



8.1 Cytotoxic drugs

Drugs for cytotoxic-induced side-effects

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
 - 8.3.4.1 Breast Cancer
 - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
 - 8.3.4.3 Somatostatin analogues

8.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NICE Guidance

Advanced breast cancer (CG81)

Familial breast cancer (CG164)

Hepatitis B (chronic) (CG165)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)

Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

Early and locally advanced breast cancer: diagnosis and management (NG101)

Lung cancer: diagnosis and management (NG122)

Prostate cancer: diagnosis and management (NG131)

Colorectal cancer (NG151)

Temozolomide for malignant glioma (TA23)

Leukaemia (lymphocytic) - fludarabine (TA29)

Trastuzumab for advanced breast cancer (TA34)

Paclitaxel for ovarian cancer (TA55)

Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)

Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)

Docetaxel for prostate cancer (hormone-refractory) (TA101)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Paclitaxel for early breast cancer (TA108)

Docetaxel for early breast cancer (TA109)

Gemcitabine for Breast Cancer (TA116)

Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)

Leukaemia (lymphocytic) - fludarabine (TA119)

Carmustine implants and temozolomide for gliomo (newly diagnosed & high grade) (TA121)

Pemetrexed for lung cancer (non small cell) (TA124)

Multiple sclerosis - natalizumab (TA127)

Bortezomib for relapsed multiple myeloma (TA129)

Pemetrexed for mesothelioma (TA135)

Rituximab for follicular non-Hodgkin's lymphoma (TA137)

Head and neck cancer - cetuximab (TA145)

Renal cell carcinoma - sunitinib (TA169)

Lenalidomide - multiple myeloma (TA171)

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

Renal Cell Carcinoma (TA178)

Sunitinib for gastrointestinal stromal tumours (TA179)

Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)

Cervical cancer (recurrent) - topotecan (TA183)

Lung cancer (small cell) - topotecan (TA184)

Soft tissue sarcoma - trabectedin (TA185)

Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)

Gastric cancer (advanced) - capecitabine (TA191)

Lung cancer (non-small-cell, first line) - gefitinib (TA192)

Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)

Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106) Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86) Colorectal cancer (metastatic) - bevacizumab (TA212)

Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)

Renal cell carcinoma (1st line metastatic) - pazopanib (TA215) Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Myelodysplastic syndrome - azacitidine (TA218)

Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)

Multiple myeloma (1st line) - bortezomib and thalidomide (TA228)

Osteosarcoma - mifamurtide (TA235)

Follicular lymphoma - rituximab (review TA110) (TA243)

Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)

Bevacizumab in combination with paclitaxel & carboplatin for 1st line treatment of advanced ovarian cancer (TA284)

Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Multiple sclerosis (relapsing) - teriflunomide (TA303)

Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

```
Multiple myeloma - bortezomib (induction therapy) (TA311)
Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)
pilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5g cytogenetic abnormality (TA322)
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Olaparib forovarian, fallopian tube and peritoneal cancer (TA381)
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Trifluridine-tipiracil for previously treated metastatic colorectal cancer (TA405)
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Nivolumab for previously treated advanced renal cell carcinoma (TA417)
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)
Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)
Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)
Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)
Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)
Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)
Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)
Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)
Cladribine tablets for treating relapsing-remitting multiple sclerosis (TA493)
Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)
Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Tivozanib for treating advanced renal cell carcinoma (TA512)
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)
Cabozantinib for treating medullary thyroid cancer (TA516)
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
```

MFT Formulary v10.11 (November 2025) Malignant disease Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519) Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520) Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522) Midostaurin for untreated acute myeloid leukaemia (TA523) Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524) Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525) Arsenic trioxide for treating acute promyelocytic leukaemia (TA526) Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527) Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528) Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531) Ocrelizumab for treating relapsing-remitting multiple sclerosis (TA533) Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535) Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536) Dinutuximab beta for treating neuroblastoma (TA538) Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540) Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541) Cabozantinib for untreated advanced renal cell carcinoma (TA542) Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544) Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545) Padeliporfin for untreated localised prostate cancer (TA546) Vandetanib for treating medullary thyroid cancer (TA550) Lenvatinib for untreated advanced hepatocellular carcinoma (TA551) Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552) Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553) Regorafenib for previously treated advanced hepatocellular carcinoma (TA555) Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559) Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561) Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562) Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563) Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569) Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571) Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577) Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579) Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580) Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584) Ocrelizumab for treating primary progressive multiple sclerosis (TA585) Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586) Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587) Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589) Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593) Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598) Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600) Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611) Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612) Cladribine for treating relapsing-remitting multiple sclerosis (TA616) Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619) Peginterferon beta-1a for treating relapsing-remitting multiple sclerosis (TA624) Lenalidomide with rituximab for previously treated follicular lymphoma (TA627) Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628) Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629) Larotrectinib for treating NTRK fusion-positive solid tumours (TA630) Trastuzumab emtansine for adiuvant treatment of HER2-positive early breast cancer (TA632) Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638) Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639) Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640) Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641) Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642) Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643) Entrectinib for treating NTRK fusion-positive solid tumours (TA644) Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645) Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649) Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650) Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653) Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654) Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655) Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657) Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660) Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663) Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666) Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668) Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670) Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

Pembrolizumab with pemetrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)

Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)

```
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)
Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)
Midostaurin for treating advanced systemic mastocytosis (TA728)
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)
Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Ponesimod for treating relapsing-remitting multiple sclerosis (TA767)
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)
Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)
Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer.... (TA786)
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
Diroximel fumarate for treating relapsing-remitting multiple sclerosis (TA794)
Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)
Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)
Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)
Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802)
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)
Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)
Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)
Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)
Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)
Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
```

```
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia...(TA893)
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)
Ruxolitinib for treating polycythaemia vera (TA921)
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)
Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)
Loncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)
lyosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA962)
Dostarlimab with platinum-based chemo for advanced / recurrent endometrial cancer with MSI-H or MMR deficiency (TA963)
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Tisagenlecleucel for treating relapsed or refractory B-cell ALL in people 25 years and under (updates & replaces TA554) (TA975)
Dabrafenib for treating BRAF V600E mutation-positive glioma in children & young people aged 1 year & over (TA977)
lvosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)
Pembrolizumab for untreated locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma (TA983)
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Pembrolizumab with platinum- and fluoropyrimidine-based chemo for untreated advanced HER2-negative gastric or GOJA (TA997)
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Quizartinib for treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)
Pembrolizumab before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable NSCLC (TA1017)
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (updates & replaces TA756) (TA1018)
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (updates & replaces TA529) (TA1021)
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)
Ublituximab for treating relapsing multiple sclerosis (TA1025)
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for resectable NSCLC (TA1030)
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy (TA1034)
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer (TA1036)
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug... (TA1038)
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug... (TA1039)
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (TA1040)
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma (TA1048)
Blinatumomab for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-cell ALL (TA1049)
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Ruxolitinib for treating acute GvHD that responds inadequately to corticosteroids in people 12 years and over (TA1054)
Rucaparib for treatment of advanced ovarian, fallopian tube & peritoneal cancer… (TA1055)
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)
Osimertinib for untreated EGFR mutation-positive advanced NSCLC (TA1060)
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)
Capivasertib for treating hormone receptor-positive HER2-negative advanced breast cancer (TA1063)
Dostarlimab for treating primary advanced or recurrent endometrial cancer with MSI-H or dMMR (TA1064)
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with MSI-H or dMMR (TA1065)
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (updates & replaces TA823) (TA1071)
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma (TA1081)
Ribociclib for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer (TA1086)
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer (terminated) (TA1089)
```

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090) Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)

Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (TA1092)

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer... (TA1097)

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (TA1099)

Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)

Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1108)

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA1109)

Abiraterone (originator & generics) for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer (TA1110)


GMMMG Formulary


Formulary Homepage

Chapter 8: Malignant disease & immunosuppression


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List
























Teriflunomide

RED (£)

RESTRICTED Specialist use only in line with NICE TA303

tablets

PDEX NICE MMC BNF emc NOT STOCKED

Thalidomide

RESTRICTED Haematology


Consultants only


Capsules

MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)


MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years

MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies









Section 9: Nutrition & blood

Supported by the formulary (click here)



9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.1.8 Haemophilia

9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance
- 9.3 Intravenous nutrition

9.4 Oral nutrition

9.4.1 Nutrition in special diets

9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

9.7 Bitters & tonics

9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Nutrition support in adults (CG32)

Coeliac disease: recognition, assessment and management (NG20)

Chronic kidney disease: assessment and management (NG203)

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

Migalastat for treating Fabry disease (HST4)

Eliglustat for treating type 1 Gaucher disease (HST5)

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)

Lumasiran for treating primary hyperoxaluria type 1 (HST25)

Hyperparathyroidsim - cinacalcet (TA117)

Thrombocytopenic purpura - romiplostim (TA221)

Thrombocytopenic purpura - eltrombopag (TA293)

Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)

Etelcalcetide for treating secondary hyperparathyroidism (TA448)

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

Patiromer for treating hyperkalaemia (TA623)

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

Avalglucosidase alfa for treating Pompe disease (TA821)

Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)


GMMMG Formulary


Formulary Homepage


Chapter 9: Nutrition & Blood


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List









Bicarbonate and lactate	
Sodium bicarbonate	
	(KIN)
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	BNF emco
Sodium lactate compound	
(Hartmann's solution) infusion	BNF emc
Water	
Water for Injections	
injection	emc ₀
9.2.2.2 Plasma & plasma substitutes	
Dextran	
Dextran 40 - 10% in sodium chloride 0.9% infusion	emc⊚
Dextrose Acid Citrate ACDA	
solution	emc _®
Gelatin	
	ES N IN
Gelofusine® infusion	BNF emco

9.3 Intravenous nutrition

BNF







Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)

NICE CG32

9.4 Oral nutrition				Gм <mark>Ж</mark> мG
Prescribers should seek advice from the MFT Nutrician Sup (pager service 07659 526240) or the Dietetic Support Team (General x64668; Renal x64478; Gastro x65781)				NICE CG32
9.4.1 Nutrition in special diets				
Sapropterin dihydrochloride				RESTRICTED
RED ££		[8]	bluetea	Tetrahydrobiopterin deficiency
Kuvan® 100mg soluble tablets	PbR X	MMC 🔠	NF emc	NHS England
LaBiNIC® probiotic drops				RESTRICTED
				prevention of NEC
LaBiNIC® probiotic drops		MMC	emc _®	



Calcium acetate with magnesium carbonate		RESTRICTED
SI		Renal Consultants only
svaren® 435mg/235mg tablets	MMC BNF emco	
anthanum		RESTRICTED
SI RED		Renal Consultants only
ewable tablets; oral powder (RED dialysis; SI non-dialysis)	MMC BNF emco	
atiromer calcium		RESTRICTED Consultants only
AMBER		in line with NICE TA623
eltassa® oral powder	NICE MMC BNF emc	
evelamer carbonate		RESTRICTED
SI	FLKBI	Renal Consultants only
envela® 800mg tablets; 2.4g; 0.8g sachets	PBR X NICE MMC BNF CMC	
ucroferric oxyhydroxide		RESTRICTED
RED EE		Renal Consultants only - 3 rd line
ewable tablets	MMC BNF emc	
5.3 Fluoride		
odium fluoride		
	ENIF	
blets, paediatric drops, dental rinse	BNF emc	
5.4 Zinc		
inc sulfate		
olvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules	BNF emco	





9.6.6 Vitamin K		
Phytomenadione		
GREEN	BNE	
Konakion® MM & Konakion® MM Paediatric injection (see also section 18.1.2)	MMC BNF emc	
Menadiol sodium phosphate		
GREEN		
oral solution; tablets	MMC BNF emc	
9.6.7 Multivitamin preparations		
Vitamins B,C		RESTRICTED
		RESTRICTED
Renavit® tablets	MMC BNF emc	
Vitamins A,D,E,K		RESTRICTED
GREY SI		Paediatric CF patients
Paravit-CF® capsules; liquid	MMC BNF emc	•


9.7 Bitters & tonics



Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use







Section 10

Supported by the



10.1 Drugs used in rheumatic diseases & gout

- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs that suppress the rheumatic disease process

Gold

Penicillamine

Antimalarials

Drugs affecting the immune response

Cytokine modulators

- 10.1.4 Gout and cytotoxic induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases

10.2 Drugs used in neuromuscular disorders

- 10.2.1 Drugs that enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants

Nocturnal leg cramps

- 10.2.3 Drugs used in neuromuscular disorders
- 10.3 Drugs for the relief of soft-tissue inflammation
 - 10.3.1 Enzymes
 - 10.3.2 Rubefacients & other topical antirheumatics
- 10.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Rheumatoid arthritis in adults: management (NG100)

Osteoarthritis in over 16s: diagnosis and management (NG226)

Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)

Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)

Hyperuricaemia - febuxostat (TA164)

Psoriasis - ustekinumab (TA180)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)

Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)

Psoriatic arthritis - golimumab (TA220)

Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)

Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)

Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Apremilast for treating active psoriatic arthritis (TA433)

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)

Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

Sarilumab for moderate to severe rheumatoid arthritis (TA485)

Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)

Tocilizumab for treating giant cell arteritis (TA518)

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Nusinersen for treating spinal muscular atrophy (TA588)

Upadacitinib for treating severe rheumatoid arthritis (TA665)

Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

Anakinra for treating Still's disease (TA685)

Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)

Ixekizumab for treating axial spondyloarthritis in adults (TA718)

Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)

Tofacitinib for treating juvenile idiopathic arthritis (TA735)

Upadacitinib for treating moderate rheumatoid arthritis (TA744)

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)

Risdiplam for treating spinal muscular atrophy (TA755)

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)

Upadacitinib for treating active ankylosing spondylitis (TA829)

Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

Bimekizumab for treating axial spondyloarthritis (TA918)

Tofacitinib for treating active ankylosing spondylitis (TA920)

Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

GMMMG Formulary


Formulary Homepage

Chapter 10: Musculoskeletal & Joint Diseases

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List


100mg; 200mg tablets





BNF emc


10.1.2 Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with	local as well as systemic adminis	stration
10.1.2.1 Systemic corticosteroids		NICE NG100
Prednisolone		
	BNF emc	
10.1.2.2 Local corticosteroid injections		NICE NG100
Hydrocortisone acetate		
GREEN		
25mg/mL injection	BNF emc	
Methylprednisolone acetate		
GREEN		
40mg/mL injection	BNF emc	
Triamcinolone acetonide		
GREEN		
10mg/mL; 40mg/mL injection	BNF emc	
Triamcinolone hexacetonide		RESTRICTED Paediatric
		Rheumatology Consultants only
20mg/mL injection	MMC BNF emc	
10.1.3 Drugs that suppress the rheumatic disease process		
Gold		NICE NG100
Auranofin		RESTRICTED Rheumatology
		Consultants only
tablets	BNF emc	
Penicillamine		
Penicillamine		RESTRICTED Rheumatology
AMBER		Consultants only
tablets (see also sections 9.8.1 & 18.1.1)	BNF emc	
Antimalarials		
Hydroxychloroquine sulfate		RESTRICTED Rheumatology
AMBER	[S]XI(F	Consultants only
tablets	MMC BNF emc	
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when the control of the control		s; reminder of psychiatric reactions
MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus	s (COVID-19) treatment	DECEMBER OF THE PARTY OF THE PA
Mepacrine hydrochloride U		RESTRICTED Rheumatology Consultants only
400 4114	BNF for children	Consultants only
100mg tablets	MMC BNF emc	NICE NC100
Drugs affecting the immune response		NICE NG100
Azathioprine AMBER	(- N - N - N - N - N - N - N - N - N -	RESTRICTED Rheumatology Consultants only
tableta, injection, and colution (see also continued 5.2, 9.24, 9.42, 5.2)	ISINIC tor children	Consultants only
tablets; injection; oral solution (see also sections 1.5.3, 8.2.1 & 13.5.3) MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy	BNF emc	
Ciclosporin		
AMBER		RESTRICTED Consultants only
capsules; oral solution; injection (see also sections 8.2.2 & 13.5.3)	MMC BNF emc	
Leflunomide	WIND CHICS	RESTRICTED Rheumatology
AMBER		Consultants only
tablets	MMC BNF emc	
Methotrexate		
AMBER RED		RESTRICTED Consultants only
tablets; injections (see also sections 1.5.3, 8.1.3 & 13.5.3)	MMC BNF emc	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to a		
MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measu		se











Non-Formulary Items		GM <mark>M</mark> MG
Diclofenac sodium		Discontinued July 2016
Dyloject® injection	MMC BNF emco	
Diclofenac sodium		
Voltarol® injection	MMC BNF @mc	
Efgartigimod alfa	initial State Circumstance	MFT not a commissioned centre
RED ff	blueteq	Patients referred to NCA
Vyvgart® injection; infusion	PBRX NICE MMC BNF emc	
Glucosamine		in line with GMMMG
with or without chondroitin	BNF	
Hyaluronan injections (DNP)		in line with GMMMG
injection including hyaluronan and sodium hyaluronate	BNF	
Naproxen with esomeprazole		in line with NICE / GMMMG
(DNP)		in the with NOL / Civiline
	BNF emco	
Satralizumab (DNP)		in line with NICE / GMMMG
Enspryng® injection	NICE BNF (emco)	
Sodium aurothiomalate		Discontinued June 2019
injection	BNF emco	

Section 11: Eye

Supported by the formulary (click here)



11.3 Anti-infective eye preparations

- 11.3.1 Antibacterials
- 11.3.3 Antivirals

11.4 Corticosteroid & other anti-inflammatory preparations

- 11.4.1 Corticosteroids
- 11.4.2 Other anti-inflammatory preparations
- 11.5 Mydriatics & cycloplegics

11.6 Treatment of glaucoma

Beta-blockers

Prostaglandin analogues and prostamides

Combination products (prostaglandin analogue with beta-blocker)

Combination products (prostaglandin analogue with Rho kinase inhibitor)

Sympathomimetics

Carbonic anhydrase inhibitors

Miotics

11.7 Local anaesthetics

11.8 Miscellaneous ophthalmic preparations

- 11.8.1 Tear deficiency, ocular lubricants & astringents
- 11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment
- 11.8.3 Other preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Glaucoma: diagnosis and management (NG81)

Age-related macular degeneration (NG82)

Diabetic retinopathy: management and monitoring (NG242)

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Macular degeneration (age related) ranibizimab & pegaptanib (TA155)

Macular oedema (retinal vein occlusion) - dexamethasone (TA229)

Macular oedema (diabetic) - ranibizumab (TA274)

Macular oedema (retinal vein occlusion) - ranibizumab (TA283)

Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)

Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)

Aflibercept for treating diabetic macular oedema (TA346)

Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

Aflibercept for treating choroidal neovascularisation (TA486)

Cenegermin for treating neurotrophic keratitis (TA532)

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uvetitis (TA590)

Brolucizumab for treating wet age-related macular degeneration (TA672)

Faricimab for treating diabetic macular oedema (TA799)

Faricimab for treating wet age-related macular degeneration (TA800)

Brolucizumab for treating diabetic macular oedema (TA820)

Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)

Fluocinolone acetonide intravitreal implant for treating chronic DMO (updates & replaces TA301 / TA613) (TA953)

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

Tebentafusp for treating advanced uveal melanoma (TA1027)


Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over (TA1093)

GMMMG Formulary


Formulary Homepage


Chapter 11: Eye


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List





Polihexanide (Polyhexamethylene biguanide (PHMB)) RED	RESTRICTED Acanthamoeba keratitis Consultant Ophthalmologist only
0.02% eye drops	
Propamidine isetionate 0	RESTRICTED Consultant
RED	Ophthalmologist only
0.1% eye drops	BNF emc
Vancomycin (ophthalmic) 0	RESTRICTED gram positives,
RED	including MRSA but not VRE
5% eye drops	BNF emc NOT STOCKED
11.3.3 Antivirals	
Ganciclovir	
SI	BNB
0.15% eye gel	BNF emc
Trifluorothymidine 0	
RED	SAL
1% eye drops	BNF emc














Section 11

Eye

Insulin eye drops
Insulin (soluble) eye drops

RESTRICTED
Consultant Ophthalmologist

Humulin S® in Systane® lubricant eye drops

MMC

Non-Formulary Items		GMMG
Cenegermin		DISCONTINUED January 2020
Oxervate ®	NICE	
Commercial eyelid cleansing preparations (DNP)		in line with GMMMG
(ONF)		
		Criterion 1
Conjunctivitis (bacterial) (DNP)		in line with GMMMG / NHSE
Chloramphenicol eye drops or ointment.		
Conjunctivitis (viral) (DNP)		in line with GMMMG / NHSE
Hypromellose eye drops		
Dry eyes / sore tired eyes (DNP)		in line with GMMMG / NHSE
Hypromellose eye drops, carbomer 980 gel, hyaluronate eye drops		
Ocriplasmin RED (f)		DISCONTINUED May 2020
Jetrea® 0.5mg/0.2mL injection	PBRX NICE MMC BNF emco	
Polymyxin B sulfate		DISCONTINUED
	BNF	November 2017
Polyfax® eye ointment	BNF emco	
Poly (carboxymethylglucose sulfate)		DISCONTINUED
		December 2019
Cacicol® eye drops (0.33mL)	MMC BNF emco	
Simple eye ointment (DNP)		in line with GMMMG
	BNF emco	Criterion 1
Tebentafusp		NOT STOCKED. Patients treated at
Red E£		commissioned centre in Liverpool
K <i>immtrak</i> ® 200micrograms/mL infusion	PBRX NICE MMC BNF emco	· ·

Section 12: Ear, nose & oropharynx

Supported by the formulary (click here



- 12.1 Drugs acting on the ear
 - 12.1.1 Otitis externa
 - 12.1.3 Removal of ear wax
- 12.2 Drugs acting on the nose
 - 12.2.1 Drugs used in nasal allergy
 - 12.2.2 Topical nasal decongestants
 - 12.2.3 Nasal preparations for infection
- 12.3 Drugs acting on the oropharynx
 - 12.3.1 Drugs for oral ulceration & inflammation
 - 12.3.2 Oropharyngeal anti-infective drugs
 - 12.3.4 Mouthwashes, gargles & dentifrices
 - 12.3.5 Treatment of dry mouth
- Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79) Sore throat (acute): antimicrobial prescribing (NG84)

Otitis media (acute): antimicrobial prescribing (NG91)

Tinnitus: assessment and management (NG155)

Otitis media with effusion in under 12s (NG233)

Allergic rhinitis (CKS)


GMMMG Formulary


Formulary Homepage


Chapter 12: Ear, nose & oropharynx

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List







Non-Formulary Items	GM <mark>M</mark> MG
Acute sore throat (DNP)	in line with GMMMG
Sore throat lozenges and sprays, analgesics	
Arachis oil / chlorobutanol	Removed Nov-25
Cerumol® ear drops all forms Coughs, colds and nasal congestion (DNP)	in line with GMMMG
Pseudoephedrine nasal sprays and oral preparations. Xylometazoline and ephedrine nasal sprays and drops	
Ear wax removal (DNP)	in line with GMMMG
Olive oil, sodium bicarbonate ear drops. Includes prior to syringing	
Mouth ulcers (DNP)	in line with GMMMG
Local anaesthetic gels, hydrocotrisone buccal tablets	
Oral thrush (DNP)	in line with GMMMG
Miconazole oral gel, nystatin oral suspension	

Section 13: Skin

Supported by the formulary (click here)



- 13.2 Emollient & barrier preparations
 - 13.2.1 Emollients
 - 13.2.2 Barrier preparations
- 13.3 Topical local anaesthetics & antipruritics
- 13.4 Topical corticosteroids
- 13.5 Preparations for eczema & psoriasis
 - 13.5.1 Preparations for eczema
 - 13.5.2 Preparations for psoriasis
 - 13.5.3 Drugs affecting the immune response Cytokine Modulators
- 13.6 Acne & Rosacea
 - 13.6.1 Topical preparations for acne
 - 13.6.2 Oral preparations for acne
- 13.7 Preparations for warts & calluses
- 13.8 Sunscreens & camouflagers
 - 13.8.1 Sunscreen preparations
- 13.9 Shampoos & other preparations for scalp/hair conditions
- 13.10 Anti-infective skin preparations
 - 13.10.1 Antibacterial preparations
 - 13.10.2 Antifungal preparations
 - 13.10.3 Antiviral preparations
 - 13.10.4 Parasiticidal preparations
 - 13.10.5 Preparations for minor cuts & abrasions
- 13.11 Skin cleansers, antiseptics & desloughing agents
 - 13.11.1 Alcohols & saline
 - 13.11.2 Chlorhexidine salts
 - 13.11.4 lodine
 - 13.11.6 Oxidisers & dyes
 - 13.11.7 Desloughing agents
- 13.12 Antiperspirants
- 13.13 Topical circulatory preparations
- 13.14 Miscellaneous preparations
- 13.15 BAD unlicensed specials list
- Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Atopic eczema in children (CG57)

Psoriasis: assessment and management (CG153)

Pressure Ulcers (CG179)

Pubic lice CKS (2011)

Scabies CKS (2011)

Acne vulgaris CKS (2014)

Head lice CKS (2015)

Surgical site infections: prevention and treatment (NG125)

Atopic dermatitis (eczema) - topical steroids (TA81)

Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)

Psoriasis - efalizumab and etanercept (TA103)

Psoriasis - infliximab (TA134)

Psoriasis - adalimumab (TA146)

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Psoriasis - ustekinumab (TA180)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)

Apremilast for treating active psoriatic arthritis (TA433)

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Dimethyl fumarate for treating moderate to severe plague psoriasis (TA475)

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Guselkumab for treating moderate to severe plague psoriasis (TA521)

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Baricitinib for treating moderate to severe atopic dermatitis (TA681)

Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

Bimekizumab for treating active psoriatic arthritis (TA916)

Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

Spesolimab for treating generalised pustular psoriasis flares (TA1070)

Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)

Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)

GMMMG Formulary


Formulary Homepage


Chapter 13: Skin

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

EMA (efalizumab)







betamethasone valerate ointment 25% in coal tar


13.4 Topical corticosteroids GMMMGCorticosteroid only preparations **NICE TA81** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration **HYDROCORTISONE Potency** Canesten HC® Mild GREEN hydrocortisone 1% plus clotrimazole 1% cream BNF emce Daktacort® Mild hydrocortisone 1%, miconazole nitrate 2% cream; ointment BNF emc Eurax-hydrocortisone® Mild hydrocortisone 0.25%, crotamiton 10% cream BNF emc® Fucidin H® Mild GREEN hydrocortisone 1%, fusidic acid 1% cream BNF emc Terra-Cortril® Mild hydrocortisone 1% oxytetracycline 3% ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate Moderate GREEN betamethasone valerate 0.025% ointment, cream BNF emc Betnovate-RD® Moderate GREEN betamethasone valerate 0.025% cream: ointment BNF emc **CLOBETASONE BUTYRATE Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions **Eumovate**® **Moderate** Clobetasone butvrate 0.05% cream: ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate **Potent** GREEN betamethasone valerate 0.1% ointment; cream; lotion; scalp lotion BNF emc Betnovate® **Potent** GREEN Betamethasone valerate 0.1% cream; ointment; scalp application; lotion BNF emc Betamethasone valerate with clioquinol **Potent** BNF emc betamethasone valerate 0.1% / clioquinol 3% ointment; cream Betamethasone valerate with neomycin sulfate Potent betamethasone valerate 0.1% / neomycin sulfate 0.5% cream; ointment BNF emc® Diprosalic ® Potent Betamethasone dipropionate 0.05%, salicylic acid 3% ointment BNF emc Fucibet® **Potent** GREEN betamethasone valerate 0.1% plus fusidic acid 2% cream BNF emc Betnovate® Potent **DERMATOLOGY ONLY**


CLOBETASOL PROPIONATE		Potency		
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions				
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of	f topical steroid withdrawal reactions			
Dermovate ®				
GREEN	IEUN (IE	Very potent		
clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	BNF emco			
Dermovate NN®				
	Leun (In	Very potent		
clobetasol propionate 0.05% / neomycin sulfate / nystatin cream	BNF			
Etrivex®				
GREEN		Very potent		
clobetasol propionate 500micrograms/g shampoo	MMC BNF emc	RESTRICTED - 1 ^{ry} Care referral		
DIFLUCORTOLONE VALERATE		Potency		
Diflucortolone valerate 0				
		Very potent		
diflucortolone valerate 0.3% oily cream	MMC emc	RESTRICTED Consultant Gynaecologist		





	(see also section 10.1.3)
	RESTRICTED
BRIF blueteg	Dermatology Consultants only
PBRX NICE MMC BNF emcs	
	RESTRICTED
	3 rd /4 th line as per NICE/GMMMG
PBR X NICE MMC BNF EMCO	
	RESTRICTED
blueteg	in line with NICE
PBRX NICE MMC BNF EMC)
	RESTRICTED
	Dermatology only in line with NICE
PBRX NICE MMC BNF EMC	
	RESTRICTED
	Dermatology only in line with NICE
PBRX NICE MMC BNF EMCO	
	RESTRICTED
BIME blueteg	Dermatology only in line with NICE
PERX NICE MMC BNF EMCO	
ModTog	RESTRICTED
	Dermatology Consultants only
PBR X NICE MMC BNF EMC	
	RESTRICTED
	in line with NICE
PBR X NICE MMC BNF EMCO	
MedTeg	RESTRICTED
BINE blueteg	Dermatology only in line with NICE
PBRX NICE MMC BNF EMC	
	RESTRICTED
	Dermatology only in line with NICE
PBRX NICE MMC BNF EMC)
	RESTRICTED
blueteq	Specialist use only in line with NICE
PBRX NICE MMC BNF @MC®	
	RESTRICTED
blueteq	Specialist use only in line with NICE
PBRX NICE MMC BNF EMC®)
	RESTRICTED
BNE blueteq	Specialist use only in line with NICE
PBRX NICE MMC BNF EMC®)
	RESTRICTED
blueteq	Dermatology only in line with NICE
PBRX NICE MMC BNF EMC	
	RESTRICTED
	Dermatology only in line with NICE
PBRX NICE MMC BNF @MC®)
	RESTRICTED
	Dermatology only in line with NICE /
PBRX NICE MMC BNF EMC®	NHSE
	RESTRICTED
blueteq	Specialist use only in line with NICE
PBRX NICE MMC BNF @CO	•
	•
	,
	PBRX NICE MMC BNF emco
















13.13 Topical circulatory preparations Topical circulatory preparations Heparinoid Hirudoid® 0.3% cream; 0.3% gel

13.14 Miscellaneous preparations				Gм <mark>Ж</mark> мG	
8-Methoxypsoralen				RESTRICTED Dermatology Consultants on	ly
10mg tablets		MMC	emc _®		
Fumaric acid esters U				RESTRICTED Dermatology Consultants on	ly
Fumaderm® tablets		MMC	emc _®		
Glucarpidase ①				RESTRICTED	
				2 nd line rescue therapy	Dute
Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4, 10.4 & 18.1.2)	PbR X	MMC (B)	NF emc		NHS England
Hyaluronic acid with lidocaine U				RESTRICTED	
				vocal cord paralysis	
Juvederm® / Belotero® injection		MMC	emc _®		

Steroid combinations			
Coal tar solution 5% in betamethasone valerate 0.025%			RESTRICTED Dermatology Consultants only
BP 5% w/w in 0.025% w/w ointment (100g)	MMC		Dermatology Consultants only
Tars			
Coal tar BP 5% w/w in YSP 🕕			RESTRICTED Dermatology Consultants only
BP 5% w/w in yellow soft paraffin (100g)	MMC		bermatology consultants only
Keratolytics			
Salicylic acid 5% in emulsifying ointment ①			RESTRICTED Dermatology Consultants only
5% w/w in emulsifying ointment (100g)	MMC		
Salicylic acid 10% in emulsifying ointment 10% w/w in emulsifying ointment (100g)	MMC	(PA)	RESTRICTED Dermatology Consultants only
Salicylic acid 20% in emulsifying ointment 20% w/w in emulsifying ointment (100g)	MMC	B	RESTRICTED Dermatology Consultants only
Miscellaneous			
Glycopyrrolate 2% w/w in cetomacrogol cream 2% w/w in cetomacrogol cream (100g)	MMC		RESTRICTED Dermatology Consultants only
Hydroquinone, hydrocortisone & tretinoin in a non-aqueous gel U	- www		RESTRICTED Dermatology Consultants only

Non-Formulary Items	Gw <mark>w</mark> wG
Bio-oil® (DNP) OTC	in line with GMMMG
radle cap (self-limiting) (DNP) OTC g. almond oil, olive oil, cradle cap shampoos	in line with GMMMG / NHSE
andruff (DNP) OTC	in line with GMMMG / NHSE
eoxycholic acid (DNP)	in line with GMMMG
iprobase ®	DISCONTINUED September 2021
eam; ointment ithranol RED	DISCONTINUED May 2021
thocream® 0.1% & 0.25% cream MMC BNF @mc® mollient bath and shower preparations without antimicrobials	
(DNP) OTC	in line with GMMMG
(DNP) OTC	in line with GMMMG / NHSE
lead lice (DNP) OTC	in line with GMMMG / NHSE
meticone, malathion, cyclomethicone, permethrin shampoos and liquids. "Bug buster" kits, nit combs. ydrocortisone (DNP)	in line with GMMMG
5% ointment; 2.5% cream and ointment Oxuridine in dimethyl sulfoxide ONP	in line with GMMMG
frequent cold sores of the lip OTC OTC	in line with GMMMG / NHSE
rgenol mebutate	WITHDRAWN February 2020
cato® 150 micrograms/g gel (face & scalp); 500 micrograms/g gel (trunk & extremities)	
IRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato ▼): suspension of the licence due to risk of skin malignancy IRA Drug Safety Update (Oct-19): Ingenol mebutate gel (Picato ▼): increased incidence of skin tumours seen in some clinical studies	
nnolin cream DNP) OTC	in line with GMMMG
g. Lansinoh HPA etanium® ((DNP)	Removed from formulary Nov-25
ilid acne (INP)	in line with GMMMG / NHSE
ild dry skin or irritant dermatitis	in line with GMMMG / NHSE
linocycline (DNP)	in line with GMMMG
iner burns and scalds DNP) BNF (EMC(S))	in line with GMMMG / NHSE
inoxidil DNP)	in line with GMMMG / NHSE
taneous foam appy rash (DNP) OTC	in line with GMMMG / NHSE
.g. barrier preparations (Sudocrem®, Metanium®)	In line with GMMMG / NHSE

Potassium hydroxide (DNP)			in line with GMMMG
MolluDab® 5% topical solution			
Proflavine cream, BPC			DISCONTINUED July 2018
.1% cream		emc⊛	· ·
Ringworm / Athlete's foot			in line with GMMMG / NHSE
opical preparations containing miconazole, clotrimazole, etc	PbR X	emc⊚	
Ruxolitinib		,	Not NICE approved
Opzelura ® 15mg/g cream	PBR X NICE MMC	emc⊛	
ilk garments (DNP)			in line with GMMMG / NHSE
ncluding <i>Dermasilk</i> ®, <i>Dreamskin</i> ®, <i>Skinnies Silk</i> ®			
Gun protection (DNP) OTC			in line with GMMMG / NHSE
Sunburn due to excessive sun exposure (DNP) OTC			in line with GMMMG / NHSE
.g. emollients, oral and topical antihistamines, analgesics			
Varts and verrucae (DNP) OTC			in line with GMMMG / NHSE
alicylic acid-containing products, glutaraldehyde			

Section 14: Immunological products & vaccines | Supported by the formulary (click here)



14.4 Vaccines & antisera

Bacillus Calmette-Guérin (BCG) vaccines

Botulism antitoxin

COVID-19 vaccine

Diphtheria vaccines (children under 10yrs old)

Diphtheria vaccines (children over 10yrs old & adults)

Haemophilus type B conjugate vaccine

Hepatitis A vaccine

Hepatitis B vaccine

Human papilloma virus vaccine

Influenza vaccine

Measles, Mumps & Rubella (MMR) vaccine

Meningococcal vaccines

Pneumococcal vaccines

Poliomyelitis vaccines

Rabies vaccines

Respiratory syncytial virus (RSV) vaccine

Tetanus vaccines

Typhoid vaccines

Varicella-zoster vaccines

14.5 Immunoglobulins

14.5.1 Normal immunoglobulin

14.5.2 Disease-specific immunoglobulins

14.5.3 Anti-D (Rh₀) immunoglobulin

Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin

Immunoglobulin follow up form

Immunoglobulin Prescribing and Administration Guidelines

Immunoglobulin Prescribing Flow Chart

Immunoglobulin request form

National Demand Programme for Immunoglobulin - Clinical Info

Non-formulary Conversion Table

NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

GMMMG Formulary

Formulary Homepage

Chapter 14: Immunological products & vaccines

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

Other Links

National Immunoglobulin Database

DH: Clinical guidelines for immunoglobulin use (2nd edition update)

Immunoglobulin handbook (HPA)

14.4 Vaccines & antisera		GMMG
MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immur	nosuppressed	
Bacillus Calmette-Guérin (BCG) vaccines		Tuberculosis: the Green Book, ch.32
Bacillus Calmette-Guérin (BCG) vaccine		
	ERIA	
injection	BNF emco	
BCG vaccine diagnostic agent (Tuberculin purified protein derivative (PPD))		
	BINE	
injection	BNF emc	
Botulism antitoxin		
Botulism antitoxin		RESTRICTED
	ISINIS	Emergencies only
injection	BNF emc	
COVID-19 vaccine	<u>Cilics</u>	Covid19: the Green Book, ch.14a
Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)		·
(D)NN(c)	12 years of age and older
	ENG OMOS	pending availability of XBB1.5
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)	BNF emc	pending availability of ABB 1.0
Distribution to vaccine (taxtozinameran)	THE STATE OF THE S	12 years of age and older
Coming at a Oni rary VDB 4.5 20mins are really at 1.5 (ODE)	for children	
Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)	BNF emc	
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)		5 to 11 year olds
	USINIE tor children	_
Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)	BNF emco	
MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023		
MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023 MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023		
MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022		
MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022		
MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022		
MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022		
MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022		
MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022 MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022		
MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022		
MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022		
MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022		
MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022		
MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022		
MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021		
MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021 MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021		
MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021		
MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021		
MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021		
MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021		
MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021		
MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021 MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine Astraz	Zeneca): current advice	
MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19	zonodaj. darroni davido	
Diphtheria vaccines (children under 10yrs old)		Diptheria: the Green Book, ch.15
Infanrix hexa®		
injection	BNF emc	
Infanrix-IPV®	Cilio	
	BINIE	
injection	BNF emco	
Repevax®	CITICS	
,	81Ma	
injection	BNF emco	
Diphtheria vaccines (children over 10yrs old & adults)	EIIIC®	Diptheria: the Green Book, ch.15
Revaxis®		
	Fe) N I E	
injection	IOINIn torchildren	
injection	BNF emc	!



14.5 Immunoglobulins



- **2.)** MFT have adopted a 'no form, no immunoglobulin' policy. All IVIg requests must have an Immunoglobulin Request Form completed via Hive.
- 3.) All immunoglobulin use MUST be recorded on the National Immunoglobulin Database.

14.5.1 Normal immunoglobulin RED	(for ITP & home treatment programmes)	GMMG
For intramuscular use		
Normal immunoglobulin injection		RESTRICTED Specialist use only
injection	PbR X BNF emc®	
For subcutaneous use		
Normal immunoglobulin injection		RESTRICTED Specialist use only
injection	PBRX MMC BNF emc	
For intravenous use		
Human normal immunoglobulin		RESTRICTED Specialist use only
injection	PBRX MMC BNF emc	
14.5.2 Disease-specific immunoglobulins		$G^{MM}G$
Hepatitis B immunoglobulin		
Hepatitis B immunoglobulin		RESTRICTED Not Stocked
injection	BNF emco	
Rabies immunoglobulin		
Rabies immunoglobulin		RESTRICTED Virology advice only
injection	MMC BNF emc	
Tetanus immunoglobulin		
Tetanus immunoglobulin injection	BNF Jemco	
Varicella-Zoster immunoglobulin	BNF CIICS	
Varicella-Zoster immunoglobulin	THAS	RESTRICTED Not Stocked
injection	BNF emco	
Cytomegalovirus (CMV) immunoglobulin		
Human normal immunoglobulin (CMV)		RESTRICTED Specialist use only
injection	MMC BNF emc	
14.5.3 Anti-D (Rh ₀) immunoglobulin		GM <mark>™</mark> MG
Anti-D (Rh ₀) immunoglobulin		
injection	NICE MMC BNF (emco)	

Non-Formulary Items	GMMG
AstraZeneca COVID-19 vaccine	DISCONTINUED May 2024
Vaxzevria® injection	MMC BNF emco
Moderna Biotech COVID-19 vaccine	DISCONTINUED
Spikevax® injection	MMC BNF emco
Novavax COVID-19 vaccine	PAUSED by JCVI
Nuvaxovid® injection	MMC BNF emc
Pediacel®	REPLACED by
	Infanrix hexa®
injection	BNF emco
Infanrix-IPV+Hib®	REPLACED by
injection	Infanrix hexa®

Section 15: Anaesthesia

Supported by the formulary (click here



15.1 General anaesthesia

- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative & analgesic post-operative drugs
 - 15.1.4.1 Benzodiazepines
 - 15.1.4.2 Non-opioid analgesics
 - 15.1.4.3 Opioid analgesics
 - 15.1.4.4 Other drugs for sedation
- 15.1.5 Neuromuscular blocking drugs

Non-depolarising neuromuscular blocking drugs

Depolarising neuromuscular blocking drugs

15.1.6 Drugs for reversal of neuromuscular blockade

Anticholinesterases

Other drugs for reversal of neuromuscular blockade

- 15.1.7 Antagonists for central & respiratory depression
- 15.1.8 Drugs for malignant hyperthermia

15.2 Local anaesthesia

Lidocaine

Bupivacaine

Levobupivacaine

Prilocaine

Ropivacaine

Tetracaine

Local Anaesthetic Toxicity

Other agents

Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Paediatric Anaesthesia Website

Children's Pain Management Website

PICU Emergency Drugs Calculator

Non-formulary Conversion Table

NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

GMMMG Formulary


Formulary Homepage

Chapter 15: Anaesthesia (ON HOLD)

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

15.1 General anaesthesia		
15.1.1 Intravenous anaesthetics		
Etomidate		
injection	BNF emco	
Ketamine RED		
	LEXIXXII F	
injection Proposal	BNF emco	
Propofol		
injection; infusion	MMO PNE OTRO	
Thiopental sodium	MMC BNF emc	
injection	BNF emco	
15.1.2 Inhalational anaesthetics		
Volatile liquid anaesthetics		
Desflurane		RESTRICTED
		Theatres only
anaesthetic agent	MMC BNF emc	
Isoflurane		
	(B) N/IF for children	
anaesthetic agent	MMC BNF emc	
Methoxyflurane		RESTRICTED ED only
Penthrox® inhalation vapour	MMO TIVE OTTO	ED Only
Sevoflurane	MMC BNF emc	
anaesthetic agent	BNF emco	
Nitrous oxide		
Nitrous oxide		
	ENT	
	BNF emc®	
Nitrous oxide 50% & oxygen 50%		
	ESING To children	
Entonox®	BNF emc®	
15.1.3 Antimuscarinic drugs		
Atropine sulfate	Control of	Adults 600microgram/1mL I.M. or I.V.
600microgram/1mL injection	BNF emco	1.111. 01 1.4.
Glycopyrronium bromide	BNP	
		Adults 200-400microgram I.V.
200micrograms/1mL; 600micrograms/3mL injection	BNF emco	
Hyoscine hydrobromide		
	(B)NJF	
400microgram/mL injection	BNF emc	
15.1.4 Sedative & analgesic post-operative drugs		
15.1.4.1 Benzodiazepines		NICE CG112
Diazepam GREEN		
	BNF for children	
tablets; liquid; injection; rectal tube (see also sections 4.1.2; 4.8.2 & 10.2.2) Lorazepam	BNF emc	
20142094111	iennie	
tablets; injection (see also sections 4.1.2 & 4.8.2)	BNF emco	
Midazolam	<u> </u>	
GREEN		
oromucosal solution; injection; infusion (see also section 4.8.2)	BNF emc®	
Midazolam with lidocaine ①		RESTRICTED Dental
RED &	(B) N (E for philitiper	conscious sedation in dental surgery
20mg/0.5mL and 10mg/0.5mL nasal solution	MMC BNF emc	/ procedures
Temazepam GREEN		
	[B) N. [F] for children	
tablets; oral solution (see also section 4.1.1) 15.1.4.2 Non-opioid analgesics	BNF emc⊚	
Ketorolac trometamol		
injection	MMC BNF emco	



15.1.8 Drugs for malignant hyperthermia

Dantrolene sodium hemiheptahydrate

Agilus® 120mg injection (see also section 18.1.2)

MMC BNF emco

MHRA Drug Safety Update (Jul-14): Intravenous dantrolene: risk of undissolved crystals

15.2 Local anaesthesia		AAGBI SAFETY GUIDELINE
15.2 Local anaesthesia		
Lidocaine hydrochloride		
Lidocaine		
0.5%, 1% & 2% injection (see also section 2.3.2)	BNF emco	
with adrenaline		
Lidocaine with adrenaline		
	ESIMIF for children	
1%, 2% injection	BNF emc	
for surface anaesthesia		
Lidocaine with chlorhexidine		
L. Cl		
Instillagel® 2% gel	BNF emc	
Lidocame		
OptiLube Active CHG Free® 2% gel	BNF emco	
Lidocaine with phenylephrine	BNF GIICS	
, , ,	IR/N/E	
Co-phenylcaine® 5% / 0.5% spray	MMC BNF emc	
Lidocaine with prilocaine		
EMLA® 5% cream	BNF emc	
Lidocaine		
	IRS NV IF	
4% topical solution	BNF emco	
Lidocaine		
	LES N. I.F. Reconsidered	
Laryngojet® 4% (160mg/4mL) jet spray Lidocaine	BNF emc	
Lidocaine		
5% ointment	ENF to childre	
Lidocaine	BNF emc	
Xylocaine ® 10% spray	BNF emc	
Lidocaine		RESTRICTED
GREY GREEN	티었었다	Specialist pain team only
Versatis® 700mg medicated plaster	MMC BNF emc	for in-patient use - not for discharge
Lidocaine with adrenaline and tetracaine U		RESTRICTED
	[2] [V] [= tor children	suturing of wounds in paediatric A&E
LAT® (Lidocaine 4%, Adrenaline 0.1% and Tetracaine 0.5%) gel	MMC BNF emc	
Bupivacaine hydrochloride		
Bupivacaine hydrochloride		
0.25% Infusion (500ml.)	BINIT OF COMMON	
0.25% Infusion (500mL) Bupivacaine hydrochloride with glucose	BNF emc⊚	
, ,	100NT	
Marcain Heavy® 0.5% Injection	BNF emc	
with adrenaline		
Bupivacaine and adrenaline		
	END	
0.25% with 1:200,000 injection	BNF emc	
Bupivacaine and adrenaline		
	ES NU FF for chaldren	
0.5% with 1:200,000 injection	BNF emco	
with other ingredients Bupivacaine and fentanyl		
<u> </u>		
0.125% with 1mg/500mL infusion	BNF emc®	
Bupivacaine and sodium chloride	BNF CITICO	
,		
0.08% in 0.9%	BNF emco	
Bupivacaine hydrochloride with glucose	<u> </u>	
20mg with 320mg/4mL spinal injection	BNF emc	

Levobupivacaine			
Levobupivacaine			
Chirocaine ® 25mg/10mL; 50mg/10mL; 75mg/10mL injection; epidural 250mg/200mL	MMC BNF	emc⊚	
Levobupivacaine with fentanyl			
	ENF		
0.1% with 2microgram/mL epidural	BNF	<u>emc⊚</u>	
Prilocaine hydrochloride			
Prilocaine hydrochloride			
	ENF for children		
Citanest® 1% injection	BNF	<u>emc⊚</u>	
Prilocaine hydrochloride			
	[B])([F]		
Prilotekal ® 2% injection	MMC BNF	<u>emc</u> ⊚	
Prilocaine with felypressin			
	[B][X][F for childner		
Octapressin® 3% cartridges (30mg/mL Citanest with 0.54micrograms/mL)	BNF	emc _®	
Ropivacaine hydrochloride			
Ropivacaine hydrochloride			For Consultant use on CDU (elective
			CS), Theatre 1 (ortho) & wards 1 & 2
	030400		(following surgery in Th. 1)
injection; infusion	MMC BNF	emc _®	
Tetracaine (amethocaine)			
Tetracaine			RESTRICTED children under 1yr by
			specific doctor request or /V team
	ERE		·
Ametop ® 4% gel	MMC BNF	<u>emc</u> ⊚	AAGBI SAFETY GUIDELINE
Local Anaesthetic Toxicity Intralipid 20%			AAGBI SAFETT GOIDELINE
intranplu 2076	(-WXN)		
200/ injection (see place section 19.1.1)	tor children		
20% injection (see also section 18.1.1) Other agents	BNF	emc _®	
Benzocaine 20% oral gel			RESTRICTED Paediatrics
RED Start ger			Oral surgery
Orajel® Extra Strength oral gel	MMC	emc _®	
Cocaine		CITIC	
60			
5% solution	for children	emc	
Ethyl chloride		CITICO	
Cryogesic ® spray	MMC	emc _®	
Mepivacaine hydrochloride	101101	00	
	EIMB		
3% injection	BNF	emc _®	
Neomycin sulfate with fluocinolone acetonide & lidocaine hydrochloride			RESTRICTED Paediatrics.
			Intra-urethral steroid ointment
Nefluan® 10g gel	MMC	emc⊕	

Non-Formulary Items

Cocaine hydrochloride



10% solution w/v



GMMG

REMOVED from formulary
October 2025

Section 16: Miscellaneous



16.1 Organ Perfusion Fluids

- 16.1.1 Cardiac Perfusion Fluids 16.1.2 Kidney / Pancreas / Liver perfusion fluids
- 16.1.3 Contrast Agents
- 16.1.4 Hydrogen / Methane breath tests
- 16.1.5 Catheter Lock Solution

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

GMMMG Formulary

Formulary Homepage

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List
GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

16.1 Organ Perfusion fluids			
16.1.1 Cardiac perfusion fluids			
Aspartate / Glutamate solution ①			
, topal tale / Glatamate collabor			
4001	84840		
Bretschneiders Histidine-Trytophan-Ketoglutarate (HTK)	MMC		
bretschileders i listidile-rrytophan-retogidiarate (i i i i v			
Custodiol Cardioplegia® solution (1000mL)	MMC	emc⊚	
Cardioplegia in Ringer's solution 0			
1000mL	MMC	emc⊕	
Cardioplegic ULTH Formula A 0			
500mL	MMC		
Cardioplegic ULTH Formula B 0			
500mL	MMC		
Sterile Concentrate for Cardioplegia infusion	1011010		
20mL	MMC	<u>emc</u>	
16.1.2 Kidney / Pancreas / Liver perfusion fluids			
Cold Storage Solution (UW solution)			
Belzer UW® (1000mL)	MMC		
Kidney Perfusion Fluid			
Soltran® (1000mL)	MMC		
Lung Perfusion solution			
Perfadex® (1000mL)	MMC		
Machine Perfusion solution			
D. (MD0 @ LIM	84840		
Belzer MPS® UW machine perfusion solution (1000mL) 16.1.3 Contrast Agents	MMC		
Gadobutrol			
Cadobattol			
Gadovist ® (1.0mmol/mL) injection	MMC	<u>emc</u> ⊚	
Gadoteric acid			
Dotarem® (0.5mmol/mL) injection	MMC	emc⊛	
Gadoxetic acid			
Primovist® (0.25mmol/mL) injection	MMC	emc _®	
Perflutren			
Luminity ® (150microlitres/mL) lipid microspheres for injection	MMC	emc _®	
Sulphur hexafluoride	1011010	CITICO	
01/0/0.: "!/!"	0.00.0		
Sono Vue ® (8microlitre/mL) injection	MMC	<u>emc</u> ⊕	
16.1.4 Hydrogen / Methane breath tests Fructose, Glucose, Lactose and Lactulose			
Tructose, Glucose, Lactose and Lactulose			RESTRICTED Gastro. only in line with
		* ESPGHAN	ESPGHAN guidelines
powder	MMC	<u>emc</u>	
16.1.5 Catheter Locking Solution			
Tetrasodium ethylene diamine tetra acetic acid (EDTA)			
KiteLock™ 4% sterile catheter lock solution	MMC	<u>emc</u> ⊕	
Trisodium citrate 30%			
Citra-Lock™ 30%	MMC	emc⊛	